

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

HIV-Related Stigma: Measurement Characteristics and Correlates among Adults Living with HIV at the Kenyan Coast

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050709
Article Type:	Original research
Date Submitted by the Author:	02-Mar-2021
Complete List of Authors:	Wanjala, Stanley; Pwani University School of Humanities and Social Sciences, Social Sciences; Ghent University Faculty of Medicine and Health Sciences, Public Health and Primary Care Nyongesa, Moses; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; Vrije Universiteit Amsterdam, Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute Mwangi, Paul; Centre for Geographic Medicine Research Coast, Clinical Neurosciences Mutua, Agnes M.; Centre for Geographic Medicine Research Coast, Clinical Neurosciences Luchters, Stanley; Ghent University Faculty of Medicine and Health Sciences, Public Health and Primary Care; Aga Khan University - Kenya, Population Health Newton, Charles; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; Oxford University, Psychiatry Abubakar, Amina A.; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; The Aga Khan University - Kenya, Institute for Human Development
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

HIV-Related Stigma: Measurement Characteristics and Correlates among Adults

Living with HIV at the Kenyan Coast

Stanley W. Wanjala^{1,2*}, Moses K. Nyongesa^{3,4}, Paul Mwangi³, Agnes M. Mutua³, Stanley Luchters^{2,5,6,7}, Charles R.J.C. Newton^{3,8,9}, Amina A Abubakar^{3,8,9,10}

¹Department of Social Sciences, Pwani University, Kilifi, Kenya

²Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

³Neuroassessment Group, KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research (Coast), Kilifi, Kenya.

⁴Department of Clinical, Neuro- & Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

⁵Burnet Institute, Melbourne, Australia

⁶Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

⁷Department of Population Health, Aga Khan University, Nairobi, Kenya

⁸Department of Public Health, Pwani University, Kilifi, Kenya

⁹Department of Psychiatry, University of Oxford, Oxford, UK

¹⁰Institute for Human Development, Aga Khan University, Nairobi, Kenya

Address of the corresponding author: Stanley W. Wanjala, Department of Social Sciences Pwani University, Box 195-80108, Kilifi, Kenya. Email: s.wanjala@pu.ac.ke

Target journal: BMJ Open

Word count: 4695

Abstract (300 words)

Objective We studied the psychometric properties of the 12-item short version of the Berger HIV stigma scale and assessed the correlates of HIV-related stigma among adults living with HIV on the Kenyan coast.

Design Cross-sectional study.

Setting Comprehensive Care and Research Centre in the Kilifi County Hospital.

Participants Adults living with HIV and on combination antiretroviral therapy were recruited and interviewed between February and April 2018 (n=450).

Main outcome measures HIV related stigma

Results 450 participants with a median age of 43 years (IQR = 36-50) took part in the study. Of these, 356 (79.1%) were female. Scale reliability and validity were high (alpha=0.80, test-retest reliability intraclass correlation coefficient =0.92). Using confirmatory factor analysis, we observed that the 12-item short version of the HIV stigma scale had a good fit for its hypothesised model (Comparative Fit Index =0.966, Tucker Lewis Index = 0.955, Root Mean Square Error of Approximation = 0.044). Multi-group confirmatory factor analysis indicated measurement invariance across gender and age groups as ΔCFI was ≤ 0.01 . Multivariate linear regression established that being female ($\beta=2.001$, 95%CI: 0.21, 3.80, $p= 0.029$), HIV status non-disclosure ($\beta=4.237$, 95%CI: 1.27, 7.20, $p= 0.005$) and co-occurrence of depressive and anxiety symptoms ($\beta=6.670$, 95%CI: 3.40, 9.94, $p<0.001$) were significant predictors of perceived HIV- related stigma and that these variables accounted for 10.2% of the explained variability in HIV-related stigma among adults living with HIV from Kilifi.

Conclusions Our results indicate that the 12-item short version of the HIV stigma scale is a valid and reliable measure of HIV stigma in Kenya. Furthermore, our study indicates that interventions aimed at reducing stigma need to take into account gender to address the specific needs of women, people who have not disclosed their HIV status, and those exhibiting symptoms of depression and anxiety, thereby improving their quality of life.

Keywords: Adults, Stigma, Predictors, HIV/AIDS, antiretroviral therapy, Psychometrics, Kenya

Article Summary

Strengths and limitations of this study

- This is the first study to report the 12-item HIV stigma scale's measurement characteristics in the sub-Saharan African context.
- We report on the correlates of HIV stigma based on a culturally adapted measurement tool with good psychometric properties.
- We cannot generalise our findings to all adults living with HIV in Kenya as data were collected from one geographical setting and excluded adults older than 60 years.
- We cannot conclude how individuals experience stigma over time because of the study design limitation.

Introduction

HIV/AIDS remains a considerable public health concern globally, with sub-Saharan Africa (SSA) bearing the most HIV-related disease burden.¹ Despite SSA making up about 11% of the earth's population, it is the world's epicentre of HIV/AIDS. By the close of 2019, an estimated 38 million people were living with HIV globally, with an estimated 68% living in SSA, accounting for two-thirds of all HIV infected individuals.¹ Estimates show that between 80% to 90% of the people living with HIV/AIDS (PLWHA) in Kenya are adults.² Between 2010 and mid-2020, there has been an upsurge in the number of people accessing antiretroviral therapy (7.8- 26 million). Further, between 2010 and 2019, new HIV infections declined by an estimated 16% from 2.1 Million/year to 1.7 million/year, and AIDS-related deaths dropped from 1.1 million to around 690,000 per year.¹

Erving Goffman³ defined stigma as a process through which individuals are 'disqualified from full social acceptance' due to an undesirable 'mark' or 'label.' This label can either be a physical, health, or behavioural attribute that is regarded as 'deeply discrediting.'³ In this study, the label is HIV seropositive status. Additionally, stigma, defined as a 'mark,' sets a person apart from others and links the person to undesirable characteristics such as stereotypes.⁴ HIV-related stigma among PLWHA is prevalent throughout SSA.⁵ HIV-related stigma has been identified as a severe obstacle in the way of effective responses to HIV.⁶

Although efforts have been scaled up to raise awareness and increase public knowledge about HIV since the epidemic started decades ago, social stigma is still associated with the disease.⁷ Research has demonstrated that stigma keeps people from adopting HIV preventive behaviours and accessing needed care and treatment⁸, negatively impacting their health and well-being. Among HIV-infected women, the decision to disclose their HIV seropositive status is likely affected by perceived stigma.⁹

From previous research, HIV stigma experienced by PLWHA can either be enacted, anticipated, or internalised.¹⁰ Enacted stigma includes an individual's experiences, prejudice, and/or discrimination from others because of one's HIV status. Anticipated stigma includes an individual's expectation of experiencing enacted stigma, while internalised stigma refers to the extent to which PLWHA have adopted negative feelings and beliefs about PLWHA.¹¹

A variety of instruments designed to measure HIV-related stigma have been published.¹²⁻²⁰ Berger's 40-item HIV stigma scale (HSS-40) is the most commonly used instrument and one of the few instruments covering all stigma mechanisms affecting PLWHA.¹¹ It takes up to 25

minutes to complete the HSS-40²¹, which may limit its application, especially in extensive surveys. Though there exist shortened versions covering 25²¹ and 32²² items of the HIV stigma scale, the 12-item HIV stigma scale (HSS-12)¹³ version of the Berger HIV stigma scale was examined in the present study as it facilitates the inclusion of HIV stigma in more extensive surveys. Furthermore, it has comparable psychometric properties to the full-length scale.¹³ While evidence from other parts of the world¹³ indicates that the HSS-12 is psychometrically sound, we are unaware of any study that has reported this scales' psychometric properties in the SSA context.

Empirical evidence indicates that sociodemographic characteristics such as age,^{23 24} gender,²⁴⁻²⁶ employment,²⁷ educational attainment,²⁸⁻³⁰ and marital status,³¹ are significantly correlated with HIV related stigma. However, the directionality is inconsistent. An explanation for the different findings regarding correlates and predictors of HIV related stigma might be due to the diverse research strategies applied and the sample composition. Research shows that stigma and disclosure of HIV status are interrelated phenomena for people living with HIV/AIDS.³² Furthermore, persons who have not disclosed their HIV status exhibit higher levels of perceived HIV-related stigma and greater levels of concern about HIV disclosure.³³

Despite the abundance of published reports on HIV related stigma and its predictors amongst specific sub-groups of the adult population, there is a paucity of research findings focusing on predictors of HIV related stigma across the entire adult population. Further, no study in the SSA context has tested for the validity and reliability of the HSS-12. This study aims to determine the correlates of HIV-related stigma among adults living with HIV from Kilifi, Coastal Kenya. Specifically, the study aims to: i) examine the psychometric properties of the 12-item Berger Stigma Scale; and ii) establish the correlates of stigma among adults living with HIV in Kilifi.

Methods

Study setting

This cross-sectional study was conducted at the Centre for Geographic Medicine Research-Coast, Kenya Medical Research Institute-Wellcome Trust Research Programme (KEMRI/WTRP). It was based at the Comprehensive Care and Research Centre (CCRC) in the Kilifi County Hospital (KCH). The majority of Kilifi County residents are poor (71.4% live below the poverty line), lack formal education, and earn a living mainly through subsistence

1
2
3 farming or fishing.³⁴⁻³⁷ HIV prevalence in adults is estimated to be at 4.5%.³⁸ The CCRC offers
4 clinical services such as management of opportunistic infections, HIV testing and counselling,
5 family planning, nutritional counselling, cervical cancer screening, and serves as a research
6 facility. About 60 patients are seen daily. By 2020, the clinic has enrolled over 9,000 patients
7 of all ages.
8
9

10 11 12 **Study participants**

13
14 This data is part of a larger project focusing on diverse outcomes in adults living with HIV,
15 including mental health and health-related quality of life. A cross-sectional survey of 450 study
16 participants among patients attending an HIV care and treatment clinic at Kilifi County
17 Hospital was conducted between February and April 2018 (Figure 1). The participation criteria
18 were age (18-60 years old) with confirmed HIV positive status, on combination antiretroviral
19 therapy, and informed consent to participate. Participants with an acute medical illness or
20 cognitive difficulties at the time of enrolment/administration of questionnaire or could not
21 understand and/or communicate in the national language (Kiswahili), which was used during
22 the administration of all study instruments, were excluded. A research team member introduced
23 the study to eligible participants when they visited the clinic for scheduled appointments. Those
24 who consented to take part responded to the instruments at the clinic.
25
26
27
28
29
30
31
32
33
34
35

36 **Data Collection Procedures**

37
38 Study data were collected and managed using REDCap electronic data capture tools hosted at
39 KEMRI Wellcome Trust Programme. Data collection instruments were interviewer-
40 administered via android tablets, in the same order, and under the same administration
41 environment. Research assistants underwent a 4-day training in research ethics and proper
42 interviewing techniques (with role-plays) and were familiarised with the tablet-based
43 questionnaires. The questionnaire administration took place in a quiet and private room within
44 the CCRC in KCH, and the interview session lasted between 30 to 45 minutes.
45
46
47
48
49
50
51

52 **Measures**

53
54 **HIV-related stigma:** The short version (HSS-12) of the Berger HIV stigma scale¹³ was used
55 to assess patient-perceived HIV-related stigma under four dimensions: i) *personalised stigma*;
56 ii) *disclosure concerns*; iii) *negative self-image*; and iv) *concerns with public attitudes*, each
57 comprising a sub-scale of the instrument. *Personalised stigma* has been suggested to represent
58
59
60

1
2
3 the enacted stigma mechanism, *disclosure concerns*, and *concerns with public attitudes*
4 dimensions have been proposed to represent anticipated stigma mechanism, and *negative self-*
5 *image* has been proposed to represent internalised stigma mechanism.¹¹ Items on this scale are
6 rated from 1-4, with (1) being “strongly disagree” and (4) “strongly agree.” The possible score
7 for each item ranges from 1 to 4 (3–12 for sub-scale), and a total score ranges between 12 and
8 48 and is derived from the summation of item scores. Higher scores designate a greater level
9 of perceived HIV-related stigma.

10
11
12
13
14
15
16 **Patient Health Questionnaire version 9 (PHQ-9)**³⁹ was administered as a measure of
17 depressive symptoms. The PHQ-9 is a nine-item scale rated on a Likert-type scale ranging
18 from 0 “not at all” to 3 “nearly every day.” Item scores are summated to derive a total score
19 ranging from 0 to 27. It has previously been found to have good internal consistency (Cronbach
20 alpha 0.78) and acceptable test-retest reliability (intraclass correlation coefficient [ICC]=0.59)
21 when used among adults living with HIV infection in Kenya⁴⁰.

22
23
24
25
26
27 **Generalised Anxiety Disorder (GAD-7)**⁴¹ was administered as a clinical measure for
28 assessing generalised anxiety disorder based on DSM-IV criteria. The GAD-7 is a seven-item
29 self-report instrument rated on a Likert-type scale ranging from 0 “not at all” to 3 “nearly every
30 day.” The scale score ranges from 0 to 21. There is reported evidence in support of the
31 reliability and validity of this scale in Kenya.⁴² Scores from PHQ-9 and GAD-7 were combined
32 to generate a variable called CMD comorbidity, indicating the co-occurrence of depressive and
33 anxiety symptoms.

34
35
36
37
38
39
40 **Sociodemographic and asset index items:** A sociodemographic questionnaire was used to
41 collect information on the participants’ age, gender, relationship status, educational level,
42 employment status, and whom they currently shared a residence. Furthermore, an asset index
43 previously used in this setting⁴³ was used to collect information about participants’ socio-
44 economic status (SES) based on disposable assets owned. Participants were asked for
45 ownership of disposable items such as radio, television, refrigerator, gas, bicycle, motorcycle,
46 and car. The final SES score had seven (7) items. A total asset score is calculated, and
47 higher scores indicate a better SES. An asset index to estimate family wealth has been
48 recommended as an alternative approach to estimating SES in settings where reliable data on
49 family income may not be available.⁴⁴

50
51
52
53
54
55
56
57 **Clinical information:** Participants’ data were extracted from the clinic’s medical record
58 database and filled into a clinical record form. This information included participants’ dates of
59

1
2
3 HIV-diagnosis, combination antiretroviral therapy initiation, most current combination
4 antiretroviral therapy regimen, cluster of differentiation 4 (CD4) cell count, viral load, recent
5 height and weight (for Body Mass Index (BMI) calculation), and data on World Health
6 Organization (WHO) clinical staging. Participants' clinical information was retrieved from
7 their clinical records after consent was granted. Patient-unique clinic numbers were used to
8 access participants' medical records.
9

14 **Instrument translation and cross-cultural adaptation**

16 The English version of the HSS-12 was forward translated by two independent bilingual
17 translators to Kiswahili and back-translated into English by two independent back translators
18 (oblivious of the original version). A group of Kenyan HIV researchers bilingual and fluent in
19 both Kiswahili and English and the translators had a harmonisation meeting to review the
20 content, conceptual, semantic, and idiomatic equivalence of the questionnaires to ensure the
21 cultural relevance of the HSS-12. The final version was obtained after the incorporation of
22 changes emerging from pretesting.
23
24
25
26
27
28
29

30 **Patient and public involvement**

31 Patients were not involved in the design and conduct of this study.
32
33
34

35 **Statistical analyses**

38 **Factor structure and measurement invariance across age-groups and gender**

39 First, Confirmatory Factor Analysis (CFA) was used to examine the HIV-stigma scale's factor
40 structure. A CFA model representing the Swahili version of the HSS-12 was set up and
41 analysed with weighted least square mean and variance adjusted (WLSMV) using the lavaan⁴⁵
42 package in R statistical software⁴⁶ on all the 450 observations. The Goodness of fit was
43 assessed using χ^2 test, Comparative Fit Index (CFI), Tucker Lewis Index (TLI), and root mean
44 square error of approximation (RMSEA). The data was expected to have a good fit to the model
45 if the χ^2 test was non-significant, CFI and TLI values were greater than 0.90, and RMSEA score
46 was lower than 0.05.⁴⁷
47
48
49
50
51
52
53

54 Secondly, after defining the model, Multi-Group Confirmatory Factor Analysis (MGCFAs)⁴⁸
55 was used to test for measurement invariance of the HSS-12 for gender and age groups. Change
56 in CFI (Δ CFI) has been suggested as a robust statistic for testing between-group invariance of
57
58
59
60

1
2
3 CFA models. Additionally, it has been recommended that invariance can be assumed when
4 Δ CFI is ≤ 0.01 in absolute values.⁴⁹
5
6

7 **Internal construct validity and convergent validity**

8
9 Means and standard deviations were used to evaluate the distribution of scores within the
10 subscale and among the items. Itemised means and standard deviations were expected to be
11 almost the same within the subscale, justifying item scores' aggregation into subscale scores.⁵⁰
12 The item-total correlation was used to evaluate internal construct validity. Each items'
13 corrected item-total correlation coefficients were calculated and expected to exceed 0.4 and
14 vary in range. Convergent validity was assessed using the Pearson correlation coefficient
15 between HSS-12, PHQ-9, and GAD-7 scores. Correlation coefficients were interpreted as small
16 (0.10–0.29), moderate (0.30–0.49), and large (0.49 and above).⁵¹
17
18
19
20
21
22

23 **Reliability**

24
25 Cronbach's alpha (α) was used to examine each subscale's internal consistency and overall
26 scores of the Swahili version of the HSS-12. Cronbach's alpha was considered acceptable if
27 greater than (>0.7).⁵² The intra-class correlation coefficient (ICC) was used to examine test-
28 retest of the Swahili version of the HSS-12 by correlating scores taken at two different time
29 points (2 weeks apart) using the same measure administered to the same participant. ICC of
30 0.60 was considered marginal, 0.70 acceptable, and anything over 0.80 considered high.⁵³
31
32
33
34
35

36 **Sample characteristics and correlates**

37
38 Frequencies and means (with percentages and standard deviations) were used to describe
39 sample characteristics. Univariate and multivariable linear regression were used to assess
40 factors associated with both stigma subscales and the overall stigma scale. In the regression
41 model, stigma scores were expressed as a continuous measure. Independent variables included
42 age, gender, marital status, education level, employment status, socioeconomic status (SES),
43 body mass index (BMI), viral load, WHO clinical stages, months since HIV diagnosis, months
44 since cART initiation, HIV status disclosure, self-reported opportunistic infections, and the co-
45 occurrence of depressive and anxiety symptoms. Our review of the literature informed factors
46 included in the model. All variables with $p < 0.20$ were included in the multivariable regression
47 model apart from viral load because participants had missing values ($n=145$). The final
48 multivariable models were generated using a backward stepwise approach by eliminating all
49 variables independently with $p > 0.05$. Assumptions of linear regression testing were visually
50 inspected through histograms (linearity), normal probability plots (normality), and plots of
51
52
53
54
55
56
57
58
59
60

1
2
3 residual versus predicted values (homoscedasticity). Multicollinearity was assessed using the
4 variance inflation factor (VIF). There were no multicollinearity problems. Modelling was
5 undertaken five times in total: once to predict overall stigma and once to predict each of the
6 four subscales. R (version 3.6.3) statistical software package was used to explore the construct
7 validity of the HSS-12. All other analyses were run using (Stata version 15.0) statistical
8 software package.
9
10
11
12
13

14 Results

15 Sample Characteristics

16
17 The 450 participants had a median age of 43 years (IQR = 36-50), ranging from 18 to 60 years.
18 The vast majority of the sample were female (79.1%), had attained basic primary level
19 education (53.1%), lived with a family member (82.4%), and were unemployed (59.8%). Less
20 than half of the study participants (43.8%) were either separated, divorced, or widowed. The
21 mean BMI was within the normal range (mean [SD] = 22.4 [4.8]). Most study participants had
22 disclosed their HIV status to others (94.0%). The median time since HIV diagnosis was 8.8
23 years (IQR = 4.67-11.50), ranging from 0 to 18 years. 417(93.7%) were in stage 1 of the WHO
24 clinical staging and 425 (95.3%) on the first-line cART regimen (Table 1). The median time
25 elapsed since cART initiation was 6.7 years (IQR = 3.67-10.00). At the time of the interview,
26 less than a fifth (18.4%) of the study participants had an opportunistic infection.
27
28
29
30
31
32
33
34
35
36

37 Perceived overall stigma scores ranged from 12 to 48, with a median score of 28 (IQR = 23-
38 33). Using PHQ-9 and GAD-7 cut-off score of ≥ 10 , which have been shown to maximise
39 specificity and sensitivity for depression⁵⁴ and general anxiety disorder⁴¹ screening, the overall
40 prevalence of depressive and anxiety was 13.8% and 5.3%, respectively, among enrolled
41 participants. The co-occurrence of depressive and anxiety symptoms was present in 4.7% of
42 the study participants.
43
44
45
46
47

48 Factor structure and measurement invariance across age groups and gender

49
50 Supplementary **Error! Reference source not found.** presents CFA results with standardised
51 correlation coefficients. Our hypothesised model that the overall stigma scale comprises four
52 sub-scales correlated was confirmed given the observed fit indexes. The χ^2 test was statistically
53 significant ($\chi^2 = 91.982$, $df = 50$, $p = 0.000$) but alternate fit measures indicated acceptable fit;
54 RMSEA: 0.044; CFI:0.966 and TLI: 0.955. These results generally indicate that the data had a
55 good fit to the model and that we can confidently use both total and sub-scale scores in this
56
57
58
59
60

1
2
3 population. Measurement invariance across age groups and gender was entirely supported
4 because Δ CFIs are lower than 0.01 in all models suggesting that measurement invariance can
5 be assumed.
6
7

8 9 **Internal construct validity and convergent validity**

10
11 The factor loading of all items on the hypothesised scale was good except for item 6 (0.21)
12 under the disclosure concern subscale. Convergent validity of the HSS-12 was demonstrated
13 by the small to moderate correlations between HSS-12 and the correlation with the following
14 relevant measures: GAD-7 ($r = 0.368$, $p < 0.001$) and PHQ-9 ($r = 0.328$, $p < 0.001$) Table 2.
15
16
17

18 19 **Reliability: Internal consistency and test-retest**

20
21 Cronbach's α for the subscales and overall scale were all > 0.7 (see Table 2) except for the
22 disclosure concern sub-scale, which was 0.53 (95%CI: 0.46, 0.60). The test-retest reliability of
23 the short 12-item version of the HIV stigma scale was excellent, 0.92 (95%CI: 0.87, 0.95).
24 Additionally, Table 2 presents descriptive statistics for the stigma scale on the item level and
25 subscale level. Corrected item-total correlation coefficients were > 0.4 for all the items apart
26 from one item (0.21) in the disclosure concerns subscale. There is a variation in the range of
27 0.46-0.88, indicating that the intended stigma concepts' broadness had been captured.
28
29
30
31
32

33 34 **Correlates of perceived HIV related stigma**

35
36 In the univariate model, it was found that being female, being separated, divorced or widowed,
37 having primary or no level of education, being self-employed or unemployed, having a low
38 asset index score, having a viral load of > 1000 copies/ml, decreased duration since HIV
39 diagnosis, decreased duration since cART initiation, HIV status non-disclosure, having any
40 current opportunistic infection and co-occurrence of depression and anxiety symptoms were
41 significantly associated with overall HIV stigma scores.
42
43
44
45

46
47 *Personalised stigma* was significantly associated with being female, being single or either
48 separated, divorced or widowed, self-employed or unemployed, having a low asset index score,
49 having a viral load of > 1000 copies/ml, having any current opportunistic infection, and the co-
50 occurrence of depressive and anxiety symptoms. *Disclosure concern* was significantly
51 associated with either being separated, divorced or widowed, having no level of education,
52 having a low asset index score, less time elapsed since HIV diagnosis, less time elapsed since
53 cART initiation, and HIV status non-disclosure. *Concern with public attitudes* was
54 significantly associated with being female, having primary or no level of education, decreased
55
56
57
58
59
60

1
2
3 duration since cART initiation, and the co-occurrence of depressive and anxiety symptoms.
4 *Negative self-image* was significantly associated with either being separated, widowed or
5 divorced, having no level of education, being self-employed or unemployed, having a viral
6 load of >1000 copies/ml, decreased duration since HIV diagnosis, decreased duration since
7 cART initiation, having any current opportunistic infection and the co-occurrence of depressive
8 and anxiety symptoms (Table 3).
9

10
11
12
13
14 When a multiple linear regression model was run, it was found that being female ($\beta=2.001$,
15 $95\%CI: 0.21, 3.80$, $p=0.029$), HIV status disclosure ($\beta=4.237$, $95\%CI: 1.27, 7.20$, $p=0.005$)
16 and co-occurrence of depressive and anxiety symptoms ($\beta=6.670$, $95\%CI: 3.40, 9.94$, $p<0.001$)
17 were significant predictors of perceived HIV stigma. Having no education was borderline
18 statistically significant ($\beta=3.318$, $95\%CI: -.01, 6.65$, $p=0.051$). Regression results indicated
19 that the model explained 10.2% of the variance and that the model was a significant predictor
20 of perceived HIV stigma $F(6, 395) = 7.46$, $p<0.001$.
21
22

23
24
25
26
27 Concerning the four subscales, we found that *personalised stigma* was positively correlated
28 with being female and the co-occurrence of depressive and anxiety symptoms. *Disclosure*
29 *concern* was inversely correlated with duration since HIV diagnosis and positively correlated
30 with having no level of education and HIV status non-disclosure. *Concerns with public*
31 *attitudes* were positively correlated with being female. *Negative self-image* was positively
32 correlated with having no level of education and the co-occurrence of depressive and anxiety
33 symptoms (Table 4).
34
35
36
37
38
39

40 Discussion

41
42 This cross-sectional analysis of data from adults living with HIV observed that the HSS-12
43 presents excellent psychometric properties. Additionally, we observed that stigma was
44 associated with both physical and mental well-being. According to our study, correlates of
45 HIV related stigma include being female, HIV status non-disclosure, and the co-occurrence of
46 depressive and anxiety symptoms. Furthermore, although having no education was borderline
47 statistically significant, we would still suggest focusing on people with no education as a risk
48 group from a programmatic point of view.
49
50
51
52
53
54
55
56
57
58
59
60

Factor structure, measurement invariance, validity and reliability of the short 12-item Swahili version of the HIV Stigma Scale

The study examined the stigma scale's psychometric properties to assess its usefulness and describe the correlates of HIV-related stigma among adults living with HIV in Kilifi. Reliability and validity were acceptable, and confirmatory factor analysis supported the four-factor solution measuring the four dimensions of HIV stigma. Cronbach's alpha for the HSS-12 among the Kenyan population is similar to the Swedish population in which the scale was developed.¹³ Although Cronbach's alpha for the adapted HSS-12 sub-scales was slightly lower (0.53-0.84) than the initial version of HSS-12 (0.80-0.88), its' alpha for the total scale was 0.80 suggesting good internal consistency.

Measurement invariance of the Swahili HSS-12 was evaluated and confirmed across main interest groups: gender and age. Our results indicated that the measurement model of the Swahili HSS-12 as a patient-reported outcome to measure perceived HIV stigma among adults is comparable across age groups and gender (Table 5).

Test-retest reliability, an indicator of scale stability over time, was of acceptable levels. The original HSS-40 has been used in diverse settings^{12 55} among adults 18 years and above reporting a test re-test reliability between (ICC=0.89-0.92). To the best of our knowledge, no study has reported the test re-test reliability of the HSS-12.

We examined the construct validity of the scale using CFA since its hypothesised structure has been published. Our results indicated that the hypothesised model fit the data well and was almost similar to what was reported by a study conducted in Sweden¹³. These results indicate that one can use both the total scores and the subscale scores and interpret the results in confidence, knowing that the items fit well together. HSS-12 evidenced convergent validity by being correlated with PHQ-9, a measure of depression, and GAD-7, a measure of anxiety in conventional ways.

The HSS-12 was reliable and valid for detecting stigma among adults living with HIV at the Kenyan Coast. Consequently, HSS-12 can be practically used as a brief screening tool for stigma-related problems both for research and clinical purposes. Future research could examine its predictive validity and evaluate its sensitivity to changes. This information would be crucial in determining its usefulness as an evaluation tool for programmes and interventions.

Correlates of Stigma

Being female was positively associated with increased perceived HIV-related stigma scores, *personalised stigma*, and *concern with public attitudes*. This finding agrees with previous studies from SSA⁵⁶ and outside^{57,27} that reported a positive association between female gender and perceived HIV related stigma. Research shows that females are more likely to suffer from stigma in patriarchal societies like ours than males.^{58 59} Research has established that the African society is less tolerant of HIV infected females than it is of HIV infected men.^{60 61} Due to women's subordinate status in society, they are often stigmatised as vectors of transmission.⁶² Furthermore, the common belief that HIV is caused by indecent sexual behaviour has worse societal consequences for women who are expected to be monogamous, unlike men in most African societies.⁶⁰ Women are often blamed counterfactually to be responsible for HIV transmission.⁶⁰ Similar processes can be assumed to be at work in the Kenyan coastal region.

HIV status disclosure was positively associated with overall HIV related stigma scores and *disclosure concerns* with persons who had not disclosed their HIV status reporting greater levels of concern about HIV disclosure concerns. Anakwa and colleagues found that PLWHA with higher levels of perceived HIV-related stigma reported greater levels of HIV disclosure concerns, therefore, less likely to disclose their status.³³ From our study, only 6% had not disclosed their status to anyone. HIV status non-disclosure might be a protective behaviour for a PLWHA to conceal their status, evade adverse reactions towards themselves, weigh other people's reactions, and as a sign of concern about the implication of their disclosure on their disclosure targets.^{63 64} Further, disclosure is not only about how or whom to disclose to, but it also entails finding good opportunities to disclose or devise means of keeping ones' status and/or medication a secret to enhance access and adherence to their treatment regimen.

The co-occurrence of depressive and anxiety symptoms influenced overall HIV related stigma scores, *personalised stigma*, and *negative self-image*. This finding corroborates previous studies among PLWHA carried out within SSA^{29 65, 25}, and outside^{66 67}, which have invariably found a significant association between HIV-related stigma and depressive symptoms. Liu and colleagues⁶⁸ reported that the more stigma PLWHA perceived, the more anxiety they experienced. Similarly, we report that HIV related stigma is significantly associated with the co-occurrence of depressive and anxiety symptoms. Additionally, an individual's perception of themselves in light of their diagnosis appears to trigger depression.⁶⁹ Screening for

1
2
3 depression, anxiety, and HIV-related stigma might provide insights on interventions that may
4 promote a positive attitude and positive self-image, thereby reducing depression, anxiety, and
5 stigma, leading to their psychological and physical well-being. Given the cross-sectional nature
6 of the study, we cannot claim causality. However, the association between co-occurrence of
7 depressive and anxiety symptoms and stigma provides the impetus for: a) longitudinal studies
8 to elucidate causal pathways; and b) targeted interventions to address both stigma and mental
9 health to improve health outcomes of adults living with HIV.

10
11
12
13
14
15
16 Other factors influencing the four subscales were also established. Having no level of education
17 was positively associated with higher reported *disclosure concerns* and *negative self-image*,
18 corroborating findings of studies carried out in Nigeria⁷⁰ and the USA.⁷¹ Lower levels of
19 education may lead to less exposure, lack of or little knowledge about HIV infection and
20 transmission. In contrast, higher levels of education might lead to higher levels of knowledge,
21 providing exposure to new ways of thinking and new sources of information about the HIV
22 pandemic resulting in the reduction of less supportive attitudes towards PLWHA.^{72 73} Previous
23 research has demonstrated that people with high levels of knowledge of the transmission routes
24 for HIV consistently had more supportive attitudes towards those with HIV demonstrating the
25 role that knowledge has in reducing the misconceptions that act to create fear and shape
26 stigma.⁷²

27
28
29
30
31
32
33
34
35
36 Months since HIV diagnosis was inversely associated with *disclosure concerns*, with persons
37 with a more recent diagnosis reporting greater levels of concern about HIV status disclosure.
38 This is consistent with a study among people living with HIV/AIDS (PLWHA) in China⁷⁴ and
39 among African Americans.⁷¹ This finding suggests that living longer with HIV is associated
40 with positive outcomes because PLWHA are likely to adjust over time to their HIV positive
41 status, receive more information, develop greater insights and understanding of the disease and
42 establish psychological mechanisms to better cope with HIV stigma leading to lower levels of
43 perceived HIV stigma.

44 45 46 47 48 49 50 **Strengths and limitations of this study**

51
52 We recognise several potential limitations in this study. First, the study was in a clinical setting
53 where our study sample consisted of adults living with HIV on cART. Compared to untreated
54 individuals living with HIV, it is likely that levels of HIV stigma would be lower in our sample
55 because it has been shown that access to ART lowers stigma.⁷⁵⁻⁷⁷ Secondly, this study is cross-
56 sectional, and hence, causality for the observed significant associations cannot be inferred. We
57
58
59
60

1
2
3 can also not conclude how individuals may experience stigma over time because of the study
4 design limitation. Finally, findings may not be generalisable to all adults living with HIV in
5 Kenya as data were collected from one geographical setting and excluded adults older than 60
6 years.
7
8
9

10 11 **Conclusions and implications**

12
13 From the study, the 12-item short version of the Berger HIV stigma scale¹³ had good
14 psychometric properties and can be recommended for research purposes. The current study
15 suggests that women, those who have not disclosed, and those experiencing co-occurring
16 symptoms of depressive and anxiety symptoms, experience a higher level of perceived HIV
17 stigma in Coastal Kenya. This finding is useful in designing future interventions to improve
18 the quality of life of people living with HIV/AIDS. We propose interventions need to take into
19 account gender to address the specific needs of women, people who have not disclosed their
20 HIV status, and those exhibiting symptoms of depression and anxiety, thereby improving their
21 quality of life. Additionally, it would be prudent to design interventions that focus on people
22 with no education as a risk group who would experience high levels of HIV perceived stigma
23 from a programmatic perspective. All these interventions will help in bettering both the
24 physical and mental well-being of HIV-infected adults.
25
26
27
28
29
30
31
32
33

34 35 **Acknowledgements**

36
37 We thank our participants for taking the time and effort to participate in this study and the
38 Comprehensive Care and Research Centre (CCRC) staff in the Kilifi County Hospital HIV care
39 and treatment clinic for their unrelenting support. We appreciate Patrick Katana Vidzo for
40 helping with the entry of clinical data. The authors acknowledge the Kenya Medical Research
41 Institute (KEMRI) Director for permission to publish this work.
42
43
44
45
46

47 48 **Footnotes**

49
50 *Author Contributions:* SWW, CN, and AA conceptualised the study. SWW, MKN and AA
51 designed the study. PM formulated study questions for tablet administration and managed the
52 data. SWW and MKN supervised data collection. SWW, MKN, and AM participated in data
53 collection. SWW and MKN analysed the data. SWW, MKN, PM, AM, SL, CN and AA
54 contributed to interpreting the data. SWW wrote the first draft of the manuscript. All authors
55 reviewed subsequent versions of the manuscript and approved the final version for submission.
56
57
58
59
60

1
2
3 The corresponding author affirms that all listed authors meet authorship criteria and that no
4 other author meeting the criteria has been omitted.
5
6
7
8

9 *Funding:* This work was supported by funding from the Medical Research Council (Grant
10 number MR/M025454/1) to AAA. This award is jointly funded by the UK Medical Research
11 Council (MRC) and the UK Department for International Development (DFID) under the
12 MRC/DFID concordant agreement and is also part of the EDCTP2 program supported by the
13 European Union.
14
15
16
17

18
19 *Disclaimer:* The funders had no role in the design, collection, analysis, interpretation and
20 manuscript writing.
21
22
23

24 *Competing interests:* The authors wish to declare no potential conflict of interest.
25
26
27

28 *Ethical approval:* The local institutional review board, Scientific and Ethics Review Board
29 (SERU; Ref KEMRI/SERU/CGMR-C/108/3594), granted ethical approval to recruit
30 participants into the study. We obtained authorisation to work in the HIV care and treatment
31 clinic from the Ministry of Health, County government of Kilifi (Ref HP/KCHS/VOL.VIX/65).
32 Study participants provided written, informed consent to be part of the study.
33
34
35
36
37

38 *Transparency:* The lead author (SWW) confirms that the manuscript is an honest, accurate,
39 and sincere account of the research being reported; no important aspects of the research have
40 been omitted; and that explanations for any discrepancies from the research as planned (and, if
41 relevant, registered) have been provided.
42
43
44
45
46

47 *Data sharing statement:* No additional data are available. Anyone interested in accessing the
48 data reported in this article is free to write to the Data Governance Committee of the KEMRI
49 Wellcome Trust Research Programme, review the application and advise as appropriate, and
50 ensure that uses are compatible with the consent obtained from participants for data collection.
51 Requests can be sent to the coordinator of the Data Governance Committee using the following
52 email: dgc@kemri-wellcome.org.
53
54
55
56
57
58
59
60

REFERENCES

1. UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet [Available from: <https://www.unaids.org/en/resources/fact-sheet/files/3352/fact-sheet.html>].
2. NACC. Kenya AIDS Response Progress Report 2014: Progress towards Zero. Nairobi, Kenya: National AIDS Control Council of Kenya, 2014.
3. Goffman E. Stigma. Notes on the Management of Spoiled Identity. New York: Simon and Shuster: Inc, 1963.
4. Jones EE, Farina A, Hastorf AH, et al. Social stigma: the psychology of marked relationships. New York: W.H. Freeman 1984.
5. Maluccio JA, Wu F, Rokon RB, et al. Assessing the Impact of Food Assistance on Stigma Among People Living with HIV in Uganda Using the HIV/AIDS Stigma Instrument—PLWA (HASI-P). *AIDS and Behavior* 2017;21(3):766-82. doi: 10.1007/s10461-016-1476-9 [published Online First: 2016/07/04]
6. Dahlui M, Azahar N, Bulgiba A, et al. HIV/AIDS Related Stigma and Discrimination against PLWHA in Nigerian Population. *PLoS One* 2015;10(12):e0143749. doi: 10.1371/journal.pone.0143749 [published Online First: 2015/12/15]
7. Toth S, J AY, DePinto N. HIV stigma: perceptions from HIV-positive and HIV-negative patients in a community dental clinic. *J Dent Res Dent Clin Dent Prospects* 2016;10(4):263-69. doi: 10.15171/joddd.2016.042 [published Online First: 2017/01/18]
8. Nyblade L, Stangl A, Weiss E, et al. Combating HIV stigma in health care settings: what works? *J Int AIDS Soc* 2009;12:15. doi: 10.1186/1758-2652-12-15 [published Online First: 2009/08/08]
9. Clark HJ, Lindner G, Armistead L, et al. Stigma, disclosure, and psychological functioning among HIV-infected and non-infected African-American women. *Women & health* 2004;38(4):57-71.
10. Lindberg MH, Wettergren L, Wiklander M, et al. Psychometric evaluation of the HIV stigma scale in a Swedish context. *PLoS One* 2014;9(12):e114867. doi: 10.1371/journal.pone.0114867 [published Online First: 2014/12/19]
11. Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. *AIDS Behav* 2009;13(6):1160-77. doi: 10.1007/s10461-009-9593-3 [published Online First: 2009/07/29]
12. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. *Research in nursing & health* 2001;24(6):518-29.
13. Reinius M, Wettergren L, Wiklander M, et al. Development of a 12-item short version of the HIV stigma scale. *Health and Quality of Life Outcomes* 2017;15(1):115. doi: 10.1186/s12955-017-0691-z [published Online First: 2017/06/01]
14. Kingori C, Reece M, Obeng S, et al. Psychometric evaluation of a cross-culturally adapted felt stigma questionnaire among people living with HIV in Kenya. *AIDS Patient Care STDS* 2013;27(8):481-8. doi: 10.1089/apc.2012.0403 [published Online First: 2013/08/24]
15. Wiklander M, Rydstrom LL, Ygge BM, et al. Psychometric properties of a short version of the HIV stigma scale, adapted for children with HIV infection. *Health Qual Life Outcomes* 2013;11(1):195. doi: 10.1186/1477-7525-11-195 [published Online First: 2013/11/15]
16. Holzemer WL, Uys LR, Chirwa ML, et al. Validation of the HIV/AIDS Stigma Instrument—PLWA (HASI-P). 2007;19(8):1002-12.

17. Stigma among mothers with HIV/AIDS. XIII International AIDS Conference, Durban, South Africa; 2000.
18. Fife BL, Wright ER. The dimensionality of stigma: a comparison of its impact on the self of persons with HIV/AIDS and cancer. *J Health Soc Behav* 2000;41(1):50-67. [published Online First: 2000/04/06]
19. Herek GM, Capitanio JP. Public reactions to AIDS in the United States: a second decade of stigma. *Am J Public Health* 1993;83(4):574-7. doi: 10.2105/ajph.83.4.574 [published Online First: 1993/04/01]
20. Sowell RL, Seals BF, Moneyham L, et al. Quality of life in HIV-infected women in the south-eastern United States. *AIDS Care* 1997;9(5):501-12. doi: 10.1080/713613191 [published Online First: 1997/12/24]
21. Jeyaseelan L, Kumar S, Mohanraj R, et al. Assessing HIV/AIDS stigma in South India: validation and abridgement of the Berger HIV stigma scale. 2013;17(1):434-43.
22. Bunn JY, Solomon SE, Miller C, et al. Measurement of stigma in people with HIV: a reexamination of the HIV Stigma Scale. *AIDS Educ Prev* 2007;19(3):198-208. doi: 10.1521/aeap.2007.19.3.198 [published Online First: 2007/06/15]
23. Emlert CA, Brennan DJ, Brennenstuhl S, et al. The impact of HIV-related stigma on older and younger adults living with HIV disease: does age matter? *AIDS care* 2015;27(4):520-28.
24. Pannetier J, Lelievre E, Le Coeur S. HIV-related stigma experiences: Understanding gender disparities in Thailand. *AIDS Care* 2016;28(2):170-8. doi: 10.1080/09540121.2015.1096888 [published Online First: 2015/10/20]
25. Endeshaw M, Walson J, Rawlins S, et al. Stigma in Ethiopia: association with depressive symptoms in people with HIV. *AIDS Care* 2014;26(8):935-9. doi: 10.1080/09540121.2013.869537 [published Online First: 2014/01/03]
26. Datta S, Bhattacharjee S, Sherpa PL, et al. Perceived HIV Related Stigma among Patients Attending ART Center of a Tertiary Care Center in Rural West Bengal, India. *Journal of clinical and diagnostic research : JCDR* 2016;10(10):VC09-VC12. doi: 10.7860/JCDR/2016/21366.8669 [published Online First: 2016/11/29]
27. Sorsdahl KR, Mall S, Stein DJ, et al. The prevalence and predictors of stigma amongst people living with HIV/AIDS in the Western Province. *AIDS Care* 2011;23(6):680-5. doi: 10.1080/09540121.2010.525621 [published Online First: 2011/03/02]
28. Yeo TED, Chu TH. Social-cultural factors of HIV-related stigma among the Chinese general population in Hong Kong. *AIDS Care* 2017;29(10):1255-59. doi: 10.1080/09540121.2017.1282601 [published Online First: 2017/01/24]
29. Cuca YP, Onono M, Bukusi E, et al. Factors associated with pregnant women's anticipations and experiences of HIV-related stigma in rural Kenya. *AIDS Care* 2012;24(9):1173-80. doi: 10.1080/09540121.2012.699669 [published Online First: 2012/07/18]
30. Girma E, Gebretsadik LA, Kaufman MR, et al. Stigma against people with HIV/AIDS in rural Ethiopia, 2005 to 2011: signs and predictors of improvement. *AIDS Behav* 2014;18(6):1046-53. doi: 10.1007/s10461-013-0611-0 [published Online First: 2013/09/28]
31. Takada S, Weiser SD, Kumbakumba E, et al. The Dynamic Relationship Between Social Support and HIV-Related Stigma in Rural Uganda. *Annals of Behavioral Medicine* 2014;48(1):26-37. doi: 10.1007/s12160-013-9576-5
32. Emlert CA. A comparison of HIV stigma and disclosure patterns between older and younger adults living with HIV/AIDS. *Aids Patient Care and Stds* 2006;20(5):350-58. doi: DOI 10.1089/apc.2006.20.350

33. Anakwa NO, Teye-Kwadjo E, Kretchy IA. Effect of HIV-Related Stigma and HIV-Related Stress on HIV Disclosure Concerns: a Study of HIV-Positive Persons on Antiretroviral Therapy at Two Urban Hospitals in Ghana. *Applied Research in Quality of Life* 2020:1-16.
34. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). *Int J Epidemiol* 2012;41(3):650-7. doi: 10.1093/ije/dys062 [published Online First: 2012/05/01]
35. Allocation(CRA) CoR. Kenya County Fact sheets: ; 2011 [Available from: http://siteresources.worldbank.org/INTAFRICA/Resources/257994-1335471959878/Kenya_County_Fact_Sheets_Dec2011.pdf accessed 22nd August 2018.
36. Statistics KNBo, Africa SfIDE. Exploring Kenya's Inequality: Pulling Apart or Pooling Together?: KNBS and SIDS Nairobi, 2013.
37. Ngugi E, Kipruto S, Samoei PJKNBOS, et al. Exploring Kenya's Inequality: Pulling Apart or Pooling Together? Kilifi County. 2013
38. NACC. Kenya HIV County Profiles - 2016: National AIDS Control Council; 2016 [49-52]. Available from: <http://nacc.or.ke/wp-content/uploads/2016/12/Kenya-HIV-County-Profiles-2016.pdf> accessed 20th August 2018.
39. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. *JAMA* 1999;282(18):1737-44. doi: 10.1001/jama.282.18.1737 [published Online First: 1999/11/24]
40. Monahan PO, Shacham E, Reece M, et al. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. *J Gen Intern Med* 2009;24(2):189-97. doi: 10.1007/s11606-008-0846-z [published Online First: 2008/11/26]
41. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092-7. doi: 10.1001/archinte.166.10.1092 [published Online First: 2006/05/24]
42. Osborn TL, Venturo-Conerly KE, Wasil AR, et al. Depression and anxiety symptoms, social support, and demographic factors among Kenyan high school students. *Journal of Child Family Studies* 2019:1-12.
43. Nyongesa MK, Mwangala PN, Mwangi P, et al. Neurocognitive and mental health outcomes and association with quality of life among adults living with HIV: a cross-sectional focus on a low-literacy population from coastal Kenya. *BMJ Open* 2018;8(9):e023914. doi: 10.1136/bmjopen-2018-023914 [published Online First: 2018/09/19]
44. Filmer D, Pritchett LHJD. Estimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. *%J Demography* 2001;38(1):115-32.
45. Rosseel Y. Lavaan: An R package for structural equation modeling and more. Version 0.5–12 (BETA). *Journal of statistical software* 2012;48(2):1-36.
46. RCore T. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org> 2016
47. Blunch N. Introduction to structural equation modeling using IBM SPSS statistics and AMOS: Sage 2012.
48. Van de Schoot R, Lugtig P, Hox J. A checklist for testing measurement invariance. *European Journal of Developmental Psychology* 2012;9(4):486-92.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
49. Cheung GW, Rensvold RB. Assessing extreme and acquiescence response sets in cross-cultural research using structural equations modeling. *Journal of cross-cultural psychology* 2000;31(2):187-212.
 50. Ware Jr JE, Gandek B, Joce. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. 1998;51(11):945-52.
 51. Cohen J. Statistical power analysis for the behavioural sciences, 2nd edn. (Hillsdale, NJ: L. Erlbaum Associates). 1988
 52. Tabachnik B, Fidell L. Using multivariate statistics (6e éd.). Boston, É.-U. U: *Pearson* 2013
 53. Streiner DL. A checklist for evaluating the usefulness of rating scales. *Canadian journal of psychiatry Revue canadienne de psychiatrie* 1993;38(2):140-8. doi: 10.1177/070674379303800214 [published Online First: 1993/03/01]
 54. Akena D, Joska J, Obuku EA, et al. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. *AIDS Care* 2013;25(10):1245-52. doi: 10.1080/09540121.2013.764385 [published Online First: 2013/02/13]
 55. Jeyaseelan L, Kumar S, Mohanraj R, et al. Assessing HIV/AIDS stigma in south India: validation and abridgement of the Berger HIV Stigma scale. *AIDS Behav* 2013;17(1):434-43. doi: 10.1007/s10461-011-0128-3 [published Online First: 2012/01/17]
 56. Nattabi B, Li J, Thompson SC, et al. Factors associated with perceived stigma among people living with HIV/AIDS in post-conflict northern Uganda. *AIDS Education and Prevention* 2011;23(3):193-205.
 57. Swendeman D, Rotheram-Borus MJ, Comulada S, et al. Predictors of HIV-related stigma among young people living with HIV. *Health Psychol* 2006;25(4):501-9. doi: 10.1037/0278-6133.25.4.501 [published Online First: 2006/07/19]
 58. Asiedu GB, Myers-Bowman KS. Gender differences in the experiences of HIV/AIDS-related stigma: a qualitative study in Ghana. *Health Care Women Int* 2014;35(7-9):703-27. doi: 10.1080/07399332.2014.895367 [published Online First: 2014/02/26]
 59. Mugoya GC, Ernst K. Gender differences in HIV-related stigma in Kenya. *AIDS Care* 2014;26(2):206-13. doi: 10.1080/09540121.2013.808733 [published Online First: 2013/06/26]
 60. Mbonu NC, van den Borne B, De Vries NK. Stigma of People with HIV/AIDS in Sub-Saharan Africa: A Literature Review. *J Trop Med* 2009;2009:145891. doi: 10.1155/2009/145891 [published Online First: 2009/01/01]
 61. Amuyunzu-Nyamongo M, Okeng'o L, Wagura A, et al. Putting on a brave face: the experiences of women living with HIV and AIDS in informal settlements of Nairobi, Kenya. *AIDS Care* 2007;19 Suppl 1(sup1):S25-34. doi: 10.1080/09540120601114618 [published Online First: 2007/03/17]
 62. Muyinda H, Seeley J, Pickering H, et al. Social aspects of AIDS-related stigma in rural Uganda. 1997;3(3):143-47.
 63. Linda P. To tell or not to tell: negotiating disclosure for people living with HIV on antiretroviral treatment in a South African setting. *SAHARA J* 2013;10 Suppl 1(sup1):S17-27. doi: 10.1080/02664763.2012.755320 [published Online First: 2013/07/17]
 64. Evangeli M, Wroe AL. HIV Disclosure Anxiety: A Systematic Review and Theoretical Synthesis. *AIDS Behav* 2017;21(1):1-11. doi: 10.1007/s10461-016-1453-3 [published Online First: 2016/07/14]
 65. Nyongesa MK, Mwangi P, Wanjala SW, et al. Prevalence and correlates of depressive symptoms among adults living with HIV in rural Kilifi, Kenya. *BMC Psychiatry*

- 2019;19(1):333. doi: 10.1186/s12888-019-2339-5 [published Online First: 2019/11/05]
66. Charles B, Jeyaseelan L, Pandian AK, et al. Association between stigma, depression and quality of life of people living with HIV/AIDS (PLHA) in South India—a community based cross sectional study. 2012;12(1):463.
67. Yi S, Chhoun P, Suong S, et al. AIDS-related stigma and mental disorders among people living with HIV: a cross-sectional study in Cambodia. 2015;10(3):e0121461.
68. Liu Y, Gong H, Yang G, et al. Perceived stigma, mental health and unsafe sexual behaviors of people living with HIV/AIDS. 2014;39(7):658-63.
69. Onyebuchi-Iwudibia O, Brown A. HIV and depression in Eastern Nigeria: the role of HIV-related stigma. *AIDS Care* 2014;26(5):653-7. doi: 10.1080/09540121.2013.844761 [published Online First: 2013/10/19]
70. Oke OO, Akinboro AO, Olanrewaju FO, et al. Assessment of HIV-related stigma and determinants among people living with HIV/AIDS in Abeokuta, Nigeria: A cross-sectional study. *SAGE Open Medicine* 2019;7:2050312119869109.
71. Galvan FH, Davis EM, Banks D, et al. HIV stigma and social support among African Americans. 2008;22(5):423-36.
72. Stephenson R. Community factors shaping HIV-related stigma among young people in three African countries. *AIDS care* 2009;21(4):403-10.
73. Cianelli R, Villegas N, De Oliveira G, et al. Predictors of HIV enacted stigma among Chilean women. 2015;24(17-18):2392-401.
74. Li Z, Morano JP, Khoshnood K, et al. HIV-related stigma among people living with HIV/AIDS in rural Central China. 2018;18(1):453.
75. Chan BT, Tsai AC, Siedner MJ. HIV Treatment Scale-Up and HIV-Related Stigma in Sub-Saharan Africa: A Longitudinal Cross-Country Analysis. *Am J Public Health* 2015;105(8):1581-7. doi: 10.2105/AJPH.2015.302716 [published Online First: 2015/06/13]
76. Wolfe WR, Weiser SD, Leiter K, et al. The impact of universal access to antiretroviral therapy on HIV stigma in Botswana. *Am J Public Health* 2008;98(10):1865-71. doi: 10.2105/AJPH.2007.122044 [published Online First: 2008/08/16]
77. Jurgensen M, Sandoy IF, Michelo C, et al. Effects of home-based voluntary counselling and testing on HIV-related stigma: findings from a cluster-randomized trial in Zambia. *Soc Sci Med* 2013;81:18-25. doi: 10.1016/j.socscimed.2013.01.011 [published Online First: 2013/02/21]

Table 1: Participant's sociodemographic characteristics

Sample Characteristics	N=450	Total sample %
Sociodemographic characteristics		
Age – years (18-60), Median (IQR)	43(14)	
Gender		
Female	356	79.1
Male	94	20.9
Marital Status		
Married/cohabiting	196	43.6
Separated /Divorced/Widowed	197	43.8
Single/Never Married	57	12.7
Education		
Tertiary	22	4.9
Secondary	66	14.7
Primary	239	53.1
None	123	27.3
Employment		
Formally employed	53	11.8
Self-employed	117	26.0
Other	11	2.4
Unemployed (including students)	269	59.8
Currently living with		
Family	371	82.4
Relative/friend	10	2.2
Alone	69	15.3
Asset index score ^a – mean (SD)	1.2(1.4)	1.4
Perceived HIV-stigma score ^b – mean (SD)	28.4(7.7)	7.7
Any current chronic illness		
No	413	91.8
Yes	37	8.2
Clinical characteristics		
BMI – kg/m ² , mean (SD), OM = 4	22.4 (4.8)	
cART regimen, OM = 4		
First-line	425	95.3
Second line	21	4.7
Viral load, OM = 145		
≤ 1000 copies/mL	265	89.6
> 1000 copies/mL	40	13.1
WHO clinical stage, OM = 5		
Stage 1	417	93.7
Stage 2	22	4.9
Stage 3	3	0.7
Stage 4	3	0.7
Months since HIV diagnosis – Median (IQR)	106 (82)	
Months since cART initiation – Median (IQR)	80.5 (76)	
Treatment Characteristics		
HIV status disclosure		
Yes	423	94.0
No	27	6.0
Any current opportunistic infection		
No	367	81.6
Yes	83	18.4
Notes: OM = Observation with missing value, SD = Standard deviation, a - score range = 0 to 7, b – score range = 12 to 48, IQR = Interquartile range		

Table 2: Descriptive statistics for items and subscales in the short form 12-item Swahili version of the HIV Stigma Scale

Item	Mean item score ^a (SD)	Corrected item correlation	Mean subscale score ^b (SD)	Reliability		Validity		Construct		
				Internal consistency (Cronbach α)	Test-Retest (ICC)	\neq	#	CFI	RMSEA	TLI
Personalised Stigma			4.86(2.56)	0.84 (95% CI; 0.81-0.86)	0.83 (95% CI; 0.71-0.90)	0.357**	0.327**			
Some people stop touching me soon they know/realise I am infected with HIV/AIDS	1.66(1.01)	0.65								
People I care for stopped calling me after knowing I suffer from AIDs.	1.63(1.00)	0.87								
I have lost friends for telling/explaining that I have AIDs.	1.59(0.96)	0.88								
Disclosure Concerns			8.74(2.37)	0.53 (95% CI; 0.45-0.60)	0.62 (95% CI; 0.36-0.77)	0.070	0.070			
Telling someone that I have AIDs is dangerous*	2.24(1.24)	0.83								
I do all I can to keep my AIDs (HIV) status secret	2.90(1.22)	0.46								
I am very careful to that person I tell about my HIV status (I am cautious/ very careful to (?of) the people I tell my HIV status)	3.60(0.78)	0.21								
Concerns about Public Attitudes			8.52(3.17)	0.83 (95% CI; 0.80-0.86)	0.79 (95% CI; 0.65-0.88)	0.187**	0.165**			
People who are suffering from AIDs are treated as if they are not like the other people.	3.05(1.18)	0.68								
People believe that a person infected with HIV is dirty.	2.74(1.26)	0.84								
Many people are worried when they are near a person infected with HIV.	2.75(1.22)	0.84								
Negative Self Image			6.32(3.00)	0.74 (95% CI; 0.70-0.80)	0.76 (95% CI; 0.60-0.86)	0.372**	0.330**			
I feel guilty because I am infected with HIV	2.11(1.23)	0.60								
People’s attitudes about HIV/AIDS makes me feel very bad.	2.23(1.25)	0.78								
I feel I am not as good as others because I’m infected with HIV.	2.01(1.23)	0.73								
Overall			28.44(7.68)	0.80(95% CI; 0.77-0.83)	0.92(95% CI; 0.87-0.95)	0.368**	0.328**	0.966	0.044	0.955

Pearson product-moment correlation coefficient; **p<0.001; # correlation between HIV stigma and PHQ-9; \neq correlation between HIV stigma and GAD-7

^aPossible score for each item 1-4; higher scores reflect a higher level of perceived HIV-related stigma

^bPossible score 3-12 on each sub-scale; higher scores reflect a higher level of perceived HIV-related stigma. ^{SD} Standard deviation. CFI = Comparative Fit Index. RMSEA = Root Mean Square Error of Approximation and TLI=Tucker Lewis Index.

Table 3: Univariate linear Regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

Independent variables	N	Personalised Stigma		Disclosure concerns		Dependent variables Public attitudes		Negative self-image		Overall HIV Stigma Score	
		B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value
Sociodemographic characteristics											
Age	450	-0.01 (-0.03, 0.02)	0.595	0.01 (-0.02, 0.02)	0.999	0.01 (-0.02, 0.04)	0.399	-0.01(-0.03, 0.03)	0.880	0.01 (-0.07, 0.08)	0.910
Gender	450		0.080		0.297		0.004		0.255		0.011
Male		Ref		Ref		Ref		Ref		Ref	
Female		0.52(-0.06, 1.10)		0.29 (-0.25, 0.83)		1.07(0.35, 1.79)		0.40 (-0.29, 1.08)		2.27(0.54, 4.01)	
Marital Status	450		0.074		0.018		0.350		0.054		0.018
Married		Ref		Ref		Ref		Ref		Ref	
Separated/Divorced/Widowed		0.54(0.03, 1.04)		0.67(0.20, 1.14)		0.25(-0.38, 0.87)		0.73(0.14, 1.32)		2.18(0.67, 3.69)	
Single/never married		0.61(-0.14, 1.37)		0.17 (-0.52, 0.87)		-0.43(-1.37, -0.51)		0.40 (-0.49, 1.28)		0.75(-1.50, 3.01)	
Education Level	450		0.424		0.003		0.026		<0.001		<0.001
Tertiary		Ref		Ref		Ref		Ref		Ref	
Secondary		-0.12(-1.36, 1.12)		0.08 (-1.06, 1.21)		0.68(-0.84, 2.21)		-0.03 (-1.46, 1.40)		0.61(-3.05, 4.26)	
Primary		-0.31(-1.43, 0.81)		0.48 (-0.55, 1.51)		1.32(-0.06, 2.70)		0.72 (-0.57, 2.01)		2.20(-1.10, 5.51)	
None		0.15(-1.01, 1.32)		1.23(0.16, 2.30)		1.80(0.36, 3.23)		1.63(0.29, 2.97)		4.81(1.38, 8.25)	
Employment Status	450		0.191		0.801		0.400		0.071		0.098
Formally Employed		Ref		Ref		Ref		Ref		Ref	
Self-employed		0.67(-0.16, 1.50)		0.27 (-0.50, 1.05)		0.46(-0.57, 1.49)		0.73(-0.24, 1.70)		2.13(-0.36, 4.62)	
Other		-0.67(-2.33, 0.99)		-0.02 (-1.57, 1.53)		-1.14(-3.20, 0.93)		-0.35 (-2.29, 1.60)		-2.17(-7.15, 2.81)	
Unemployed		0.51(-0.25, 1.26)		0.33 (-0.37, 1.03)		0.18(-0.76, 1.11)		1.03(0.15, 1.91)		2.04(-0.22, 4.30)	
Currently living with	450		0.575		0.714		0.974		0.889		0.897
Immediate family		Ref		Ref		Ref		Ref		Ref	
Relative/friend		0.86(-0.75, 2.47)		0.02(-1.47, 1.52)		0.18(-1.82, 2.18)		-0.45(-2.34, 1.45)		0.62(-4.23, 5.46)	
Alone		0.01(-0.65, 0.66)		-0.25(-0.87, 0.36)		-0.06(-0.88, 0.76)		-0.07(-0.84, 0.70)		-0.38(-2.36, 1.60)	
Asset index score^a – mean (SD)	450	-0.12(-0.29-0.05)	0.171	-0.13(-0.29-0.03)	0.109	-0.11(-0.33-0.10)	0.310	-0.12(-0.32-0.08)	0.244	-0.48(-1.00-0.04)	0.068
Clinical characteristics											
BMI – kg/m², mean (SD), OM = 4		0.004(-0.04, 0.05)	0.855	-0.03(-0.07,0.02)	0.244	0.03(-0.03,0.09)	0.309	-0.03(-0.18,0.12)	0.708	-0.03(-0.18,0.12)	0.708
Viral Load OM = 145	305		0.183		0.805		0.894		0.033		0.173
≤ 1000 copies/ml		Ref		Ref		Ref		Ref		Ref	
> 1000 copies/ml		0.58(-0.28, 1.44)		0.10(-0.70, 0.90)		0.07(-1.00, 1.14)		1.05(0.08,2.02)		1.81(-0.79, 4.40)	
Months since HIV diagnosis	450	0.00(-0.00, 0.01)	0.346	-0.01(-0.01, -0.00)	<0.001	-0.00(-0.01,0.00)	0.630	-0.01(-0.01,0.00)	0.058	-0.01(-0.03,0.00)	0.091
Months since cART initiation OM = 4	446	0.00(-0.00,0.01)	0.497	-0.01(-0.01, -0.00)	0.001	-0.00(-0.01,0.00)	0.202	-0.01(-0.01, -0.00)	0.0308	-0.02(-0.03, -0.00)	0.031
Treatment characteristics											
HIV status disclosure	450		0.651		<0.001		0.287		0.228		0.023

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Yes		Ref		Ref		Ref		Ref		Ref
No		0.23(-0.77,1.23)		1.86(0.94,2.77)	0.768	0.67(-0.57,1.91)		0.72(-0.45,1.89)		3.47(0.49,6.46)
Any current opportunistic infections	450		0.037			0.759		0.017		0.065
No										
Yes		0.65(0.04,1.26)		0.09(-0.48,0.65)	0.741	0.12(-0.64,0.88)		0.87(0.16,1.59)		1.72(-0.11,3.55)
CMD comorbidity OM = 48	402		<0.001			0.145		<0.001		<0.001
Absence		Ref		Ref		Ref		Ref		Ref
Presence		2.71(1.58, 3.84)		0.18 (-0.91, 1.28)		1.09(-0.38, 2.55)		3.07(1.76, 4.39)		7.06(3.71, 10.41)

Notes: Overall stigma scale represents the sum of all twelve items from the four subscales; A negative stigma score indicates less stigma. Bolded are variables taken into multivariate linear regression. *CMD* – symptoms of depression and anxiety, *BMI* body mass index, *WHO* world health organisation, *Ref* - Reference category, *OM* observation with missing value, *cART* combination antiretroviral therapy, *a* score range = 0 to 7, *b* score range = 12 to 48.

For peer review only

Table 4: Multivariate linear Regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

Independent variables	Dependent variables									
	Personalised stigma (n=402)		Disclosure concerns (n=450)		Public attitudes (n=450)		Negative self-image (n=402)		Overall HIV Stigma Score (n=402)	
	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value
Sociodemographic characteristics										
Gender										
Male	Ref				Ref				Ref	
Female	0.75(0.17, 1.34)	0.012			1.07(0.35,1.79)	0.003			2.00(0.21,3.80)	0.029
Education Level										
Tertiary			Ref				Ref		Ref	
Secondary			-0.04(-1.14,1.07)	0.950			-0.05(-1.44,1.33)		-0.34(-3.83,3.16)	0.850
Primary			0.48(-0.52,1.48)	0.346			0.51(-0.73,1.74)		1.37(-1.75,4.50)	0.388
None			1.24(0.20,2.28)	0.019			1.33(0.04, 2.62)	0.044	3.32(-0.01,6.65)	0.051
Clinical characteristics										
Months since HIV diagnosis			-0.01(-0.01, -0.00)	0.007						
Treatment characteristics										
HIV status disclosure										
Yes			Ref						Ref	
No			1.79(0.88,2.70)	<0.001					4.24(1.27,7.20)	0.005
CMD comorbidity										
Absence	Ref						Ref		Ref	
Presence	2.67(1.55, 3.79)	<0.001					3.04(1.74, 4.34)	<0.001	6.67(3.40,9.94)	<0.001
Variance explained by the model Pseudo R-squared	6.76%		8.66%		1.89%		7.71%		10.17%	
Notes: Overall stigma scale represents the sum of all twelve items from the four sub-scales. Bolded are statistically significant values – symptoms of depression and anxiety, 95% CI - 95% confidence interval, Ref reference category										

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 5: Multi-Group Confirmatory Factor Analysis for age and gender sub-groups

Invariance Steps	Gender	RMSEA	TLI	CFI	ΔCFI	Age	RMSEA	TLI	CFI	ΔCFI
Configural Invariance	Female	0.051	0.934	0.950		Older adults	0.040	0.960	0.970	
	Male	0.051	0.934	0.950		Young Adults	0.040	0.960	0.970	
Metric Invariance	Female	0.052	0.932	0.943	0.007	Older adults	0.042	0.957	0.964	0.006
	Male	0.052	0.932	0.943	0.007	Young Adults	0.042	0.957	0.964	0.006
Scalar Invariance	Female	0.050	0.936	0.943	0.000	Older adults	0.041	0.959	0.963	0.001
	Male	0.050	0.936	0.943	0.000	Young Adults	0.041	0.959	0.963	0.001
Strict Invariance	Female	0.048	0.941	0.942	0.001	Older adults	0.041	0.959	0.960	0.003
	Male	0.048	0.941	0.942	0.001	Young Adults	0.041	0.959	0.960	0.003

Notes: CFI = Comparative Fit Index. RMSEA = Root Mean Square Error of Approximation and TLI=Tucker Lewis Index. Configural invariance - no constraints; Full metric invariance with all factor loadings constrained equal. Scalar invariance - with all intercepts constrained equal: Measurement invariance is assumed when ΔCFI is ≤0.01

Peer review only





Figure 1: Study recruitment flow chart



Supplementary Figure 1: Confirmatory factor analysis of the short version of the HIV Stigma Scale. Results show correlations between subscales (circles) and maximum likelihood estimates for the relation between subscales and items (rectangles). Sample (n = 435). Maximum likelihood estimates are standardised

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6&8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, describe analytical methods taking account of sampling strategy	8-9
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	29
		(b) Give reasons for non-participation at each stage - see details in figure 1	29
		(c) Consider use of a flow diagram	29
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	23
Outcome data	15*	Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	25-27
		(b) Report category boundaries when continuous variables were categorized - see details in Table 1	23
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Measurement characteristics and correlates of HIV-related stigma among adults living with HIV: A cross-sectional study from coastal Kenya

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050709.R1
Article Type:	Original research
Date Submitted by the Author:	14-Sep-2021
Complete List of Authors:	Wanjala, Stanley; Ghent University Faculty of Medicine and Health Sciences, Public Health and Primary Care; Pwani University School of Humanities and Social Sciences, Social Sciences Nyongesa, Moses; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; Vrije Universiteit Amsterdam, Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute Mwangi, Paul; Centre for Geographic Medicine Research Coast, Clinical Neurosciences Mutua, Agnes M.; Centre for Geographic Medicine Research Coast, Clinical Neurosciences Luchters, Stanley; Ghent University Faculty of Medicine and Health Sciences, Public Health and Primary Care; Aga Khan University - Kenya, Population Health Newton, Charles; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; Oxford University, Psychiatry Abubakar, Amina A.; Centre for Geographic Medicine Research Coast, Clinical Neurosciences; The Aga Khan University - Kenya, Institute for Human Development
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Infectious diseases, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Measurement characteristics and correlates of HIV-related stigma among adults living**
4
5 **with HIV: A cross-sectional study from coastal Kenya**
6
7

8 Stanley W. Wanjala^{1,2*}, Moses K. Nyongesa^{3,4}, Paul Mwangi³, Agnes M. Mutua³, Stanley
9 Luchters^{1,5,6}, Charles R.J.C. Newton^{3,7,8}, Amina A Abubakar^{3,7,8,9}

10
11 ¹Department of Public Health and Primary Care, Ghent University, Ghent, Belgium

12
13 ²Department of Social Sciences, Pwani University, Kilifi, Kenya

14
15 ³Neuroassessment Group, KEMRI/Wellcome Trust Research Programme, Centre for
16 Geographic Medicine Research (Coast), Kilifi, Kenya.

17
18 ⁴Department of Clinical, Neuro- & Developmental Psychology, Vrije Universiteit
19 Amsterdam, Amsterdam, Netherlands

20
21 ⁵Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
22 Australia

23
24 ⁶Department of Population Health, Aga Khan University, Nairobi, Kenya

25
26 ⁷Department of Public Health, Pwani University, Kilifi, Kenya

27
28 ⁸Department of Psychiatry, University of Oxford, Oxford, UK

29
30 ⁹Institute for Human Development, Aga Khan University, Nairobi, Kenya
31
32
33
34
35
36
37
38
39
40
41

42 ***Address of the corresponding author:*** Stanley W. Wanjala, Department of Social Sciences
43 Pwani University, Box 195-80108, Kilifi, Kenya. Email: s.wanjala@pu.ac.ke
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Abstract

2 **Objective** We studied the psychometric properties of the 12-item short version of the Berger
3 HIV stigma scale and assessed the correlates of HIV-related stigma among adults living with
4 HIV on the Kenyan coast.

5 **Design** Cross-sectional study.

6 **Setting** Comprehensive Care and Research Centre in the Kilifi County Hospital.

7 **Participants** Adults living with HIV on combination antiretroviral therapy were recruited and
8 interviewed between February and April 2018 (n=450).

9 **Main outcome measures** HIV-related stigma

10 **Results** 450 participants with a median age of 43 years (interquartile range [IQR] = 36-50)
11 took part in the study. Of these, 356 (79.1%) were female. Scale reliability and validity were
12 high ($\alpha=0.80$, test-retest reliability intraclass correlation coefficient =0.92). Using
13 confirmatory factor analysis, we observed that the 12-item short version of the HIV stigma
14 scale had a good fit for its hypothesised model (Comparative Fit Index =0.966, Tucker Lewis
15 Index = 0.955, Root Mean Square Error of Approximation = 0.044). Multi-group confirmatory
16 factor analysis indicated measurement invariance across gender and age groups as ΔCFI was
17 ≤ 0.01 . Multivariate linear regression established that being female ($\beta=2.001$, 95%CI: 0.21,
18 3.80, $p= 0.029$), HIV status non-disclosure ($\beta=4.237$, 95%CI: 1.27, 7.20, $p= 0.005$) and co-
19 occurrence of depressive and anxiety symptoms ($\beta=6.670$, 95%CI: 3.40, 9.94, $p<0.001$) were
20 significant predictors of perceived HIV-related stigma and that these variables accounted for
21 10.2% of the explained variability in HIV-related stigma among adults living with HIV from
22 Kilifi.

23 **Conclusions** Our results indicate that the 12-item short version of the HIV stigma scale is a
24 valid and reliable measure of HIV stigma in Kenya. Furthermore, our study indicates that
25 interventions aimed at reducing stigma need to take into account gender to address the specific
26 needs of women, people who have not disclosed their HIV status, and those exhibiting
27 symptoms of depression and anxiety, thereby improving their quality of life.

28 **Keywords:** Adults, Stigma, Predictors, HIV/AIDS, antiretroviral therapy, Psychometrics,
29 Kenya

1
2
3 **30 Article Summary**
4
5

6 **31 Strengths and limitations of this study**
7

- 8
9 • This is the first study to report the 12-item HIV stigma scale's measurement
10 characteristics in the sub-Saharan African context.
11
12 • We report on the correlates of HIV stigma based on a culturally adapted measurement
13 tool with good psychometric properties.
14
15 • We cannot generalise our findings to all adults living with HIV in Kenya as data were
16 collected from one geographical setting and excluded adults older than 60 years.
17
18 • We cannot conclude how individuals experience stigma over time because of the study
19 design limitation.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 Introduction

41 HIV/AIDS remains a considerable public health concern globally, with sub-Saharan Africa
42 (SSA) bearing the most HIV-related disease burden.¹ Despite SSA making up about 11% of
43 the earth's population, it is the world's epicentre of HIV/AIDS. By the close of 2019, an
44 estimated 38 million people were living with HIV globally, with an estimated 68% living in
45 SSA, accounting for two-thirds of all individuals living with HIV.¹ Between 2010 and mid-
46 2020, there has been an upsurge in the number of people accessing antiretroviral therapy (7.8-
47 26 million).¹ Further, between 2010 and 2019, new HIV infections declined by an estimated
48 16% from 2.1 million/year to 1.7 million/year, and AIDS-related deaths dropped from 1.1
49 million to around 690,000 per year.¹ By the end of 2019, an estimated 1.5 million Kenyans
50 were living with HIV, with 42,000 new infections and 21,000 AIDS-related deaths reported.²
51 Estimates show that between 80% to 90% of the people living with HIV/AIDS (PLWHA) in
52 Kenya are adults.³ Additionally, 75% of adults in Kenya are reported to be on antiretroviral
53 treatment.²

54 Erving Goffman⁴ defined stigma as a process through which individuals are 'disqualified from
55 full social acceptance' due to an undesirable 'mark' or 'label.' This label can either be a
56 physical, health, or behavioural attribute that is regarded as 'deeply discrediting.'⁴ In this study,
57 the label is HIV seropositive status. Additionally, stigma, defined as a 'mark,' sets a person
58 apart from others and links the person to undesirable characteristics such as stereotypes.⁵ HIV-
59 related stigma among PLWHA is prevalent throughout SSA.⁶ HIV-related stigma has been
60 identified as a severe obstacle in the way of effective responses to HIV.⁷

61 Although efforts have been scaled up to raise awareness and increase public knowledge about
62 HIV since the epidemic started decades ago, social stigma is still associated with the disease.⁸
63 Research has demonstrated that stigma keeps people from adopting HIV preventive behaviours
64 and accessing needed care and treatment,⁹ negatively impacting their health and well-being.
65 Among women living with HIV, the decision to disclose their HIV seropositive status is likely
66 affected by perceived stigma.¹⁰

67 From previous research, HIV stigma experienced by PLWHA can either be enacted,
68 anticipated, or internalised.¹¹ Enacted stigma includes an individual's experiences, prejudice,
69 and/or discrimination from others because of one's HIV status. Anticipated stigma includes an
70 individual's expectation of experiencing enacted stigma, while internalised stigma refers to the
71 extent to which PLWHA have adopted negative feelings and beliefs about PLWHA.¹²

1
2
3 72 A variety of instruments designed to measure HIV-related stigma have been published.¹³⁻²¹
4
5 73 Berger's 40-item HIV stigma scale (HSS-40) is the most commonly used instrument and one
6
7 74 of the few instruments covering all stigma mechanisms affecting PLWHA.¹² It takes up to 25
8
9 75 minutes to complete the HSS-40²², which may limit its application, especially in extensive
10
11 76 surveys. Though shortened versions covering 25²² and 32²³ items of the HIV stigma scale exist,
12
13 77 the 12-item HIV stigma scale (HSS-12)¹⁴ version of the Berger HIV stigma scale was examined
14
15 78 in the present study as it facilitates the inclusion of HIV stigma in more extensive surveys.
16
17 79 Furthermore, it has comparable psychometric properties to the full-length scale.¹⁴ While
18
19 80 evidence from other parts of the world¹⁴ indicates that the HSS-12 is psychometrically sound,
20
21 81 we are unaware of any study that has reported this scales' psychometric properties in the SSA
22
23 82 context.

23 83 Empirical evidence indicates that sociodemographic characteristics such as age,^{24 25} gender,²⁵⁻
24
25 84 ²⁷ employment,²⁸ educational attainment,²⁹⁻³¹ and marital status,³² are significantly correlated
26
27 85 with HIV-related stigma. However, the directionality is inconsistent. An explanation for the
28
29 86 different findings regarding correlates and predictors of HIV-related stigma might be due to
30
31 87 the diverse research strategies applied and the sample composition. Research shows that stigma
32
33 88 and disclosure of HIV status are interrelated phenomena for people living with HIV/AIDS.³³
34
35 89 Furthermore, persons who have not disclosed their HIV status exhibit higher levels of
36
37 90 perceived HIV-related stigma and greater levels of concern about HIV disclosure.³⁴

37 91 Despite the abundance of published reports on HIV-related stigma and its predictors amongst
38
39 92 specific sub-groups of the adult population, there is a paucity of research findings focusing on
40
41 93 predictors of HIV-related stigma across the entire adult population. Further, no study in the
42
43 94 SSA context has tested for the validity and reliability of the HSS-12. This study aims to
44
45 95 determine the correlates of HIV-related stigma among adults living with HIV from Kilifi,
46
47 96 Coastal Kenya. Specifically, the study aims to: i) examine the psychometric properties of the
48
49 97 12-item Berger Stigma Scale; and ii) establish the correlates of stigma among adults living with
50
51 98 HIV in Kilifi.

52 99 **Methods**

54 100 **Study setting**

56
57 101 This cross-sectional study was conducted at the Kenya Medical Research Institute-Wellcome
58
59 102 Trust Research Programme (KEMRI-WTRP), Centre for Geographic Medicine
60

1
2
3 103 Research(Coast), Kilifi, Kenya. It was based at the Comprehensive Care and Research Centre
4 (CCRC) in the Kilifi County Hospital (KCH). The majority of Kilifi County residents are poor
5 104 (71.4% live below the poverty line), lack formal education, and earn a living mainly through
6 105 subsistence farming or fishing.³⁵⁻³⁷ HIV prevalence in adults is estimated to be at 4.5%.³⁸ The
7 106 CCRC offers clinical services such as management of opportunistic infections, HIV testing and
8 107 counselling, family planning, nutritional counselling, cervical cancer screening, the
9 108 dispensation of antiretroviral therapy (ART), and serves as a research facility. About 60
10 109 patients are seen daily. By 2020, the clinic has enrolled over 9,000 patients of all ages.
11 110

111 **Study participants**

112 This data is part of a larger project focusing on diverse outcomes in adults living with HIV,
113 including mental health and health-related quality of life. A cross-sectional survey of 450 study
114 participants among patients attending an HIV care and treatment clinic at Kilifi County
115 Hospital was conducted between February and April 2018 (Figure 1). The participation criteria
116 were age (18-60 years old) with confirmed HIV positive status, on combination antiretroviral
117 therapy, and informed consent to participate. Participants with an acute medical illness or
118 cognitive difficulties at the time of enrolment/administration of questionnaire or could not
119 understand and/or communicate in the national language (Kiswahili), which was used during
120 the administration of all study instruments, were excluded. A research team member introduced
121 the study to eligible participants when they visited the clinic for scheduled appointments. Those
122 who consented to take part responded to the instruments at the clinic.
123

124 **Data Collection Procedures**

125 Study data were collected and managed using REDCap electronic data capture tools hosted at
126 KEMRI Wellcome Trust Programme^{39 40}. REDCap (Research Electronic Data Capture) is a
127 secure, web-based software platform designed to support data capture for research studies,
128 providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data
129 manipulation and export procedures; 3) automated export procedures for seamless data
130 downloads to common statistical packages; and 4) procedures for data integration and
131 interoperability with external sources. Data collection instruments were interviewer-
132 administered via android tablets, in the same order, and under the same administration
133 environment. Research assistants underwent a 4-day training in research ethics and proper
134 interviewing techniques (with role-plays) and were familiarised with the tablet-based
60

1
2
3 135 questionnaires. The questionnaire administration took place in a quiet and private room within
4
5 136 the CCRC in KCH, and the interview session lasted between 30 to 45 minutes.
6
7 137

8 9 138 **Measures**

10
11 139 **HIV-related stigma:** The short version (HSS-12) of the Berger HIV stigma scale¹⁴ was used
12
13 140 to assess patient-perceived HIV-related stigma under four dimensions: i) *personalised stigma*;
14
15 141 ii) *disclosure concerns*; iii) *negative self-image*; and iv) *concerns with public attitudes*, each
16
17 142 comprising a sub-scale of the instrument. *Personalised stigma* has been suggested to represent
18
19 143 the enacted stigma mechanism, *disclosure concerns*, and *concerns with public attitudes*
20
21 144 dimensions have been proposed to represent anticipated stigma mechanism, and *negative self-*
22
23 145 *image* has been proposed to represent internalised stigma mechanism.¹² Items on this scale are
24
25 146 rated from 1-4, with (1) being “strongly disagree” and (4) “strongly agree.” The possible score
26
27 147 for each item ranges from 1 to 4 (3–12 for sub-scale), and a total score ranges between 12 and
28
29 148 48 and is derived from the summation of item scores. Higher scores designate a greater level
30
31 149 of perceived HIV-related stigma.

32
33 150 **Patient Health Questionnaire version 9 (PHQ-9)**⁴¹ was administered as a measure of
34
35 151 depressive symptoms. The PHQ-9 is a nine-item scale rated on a Likert-type scale ranging
36
37 152 from 0 “not at all” to 3 “nearly every day.” Item scores are summated to derive a total score
38
39 153 ranging from 0 to 27. It has previously been found to have good internal consistency (Cronbach
40
41 154 alpha 0.78) and acceptable test-retest reliability (intraclass correlation coefficient [ICC]=0.59)
42
43 155 when used among adults living with HIV infection in Kenya.⁴²

44
45 156 **Generalised Anxiety Disorder (GAD-7)**⁴³ was administered as a clinical measure for
46
47 157 assessing generalised anxiety disorder based on DSM-IV criteria. The GAD-7 is a seven-item
48
49 158 self-report instrument rated on a Likert-type scale ranging from 0 “not at all” to 3 “nearly every
50
51 159 day.” The scale score ranges from 0 to 21. There is evidence in support of the reliability and
52
53 160 validity of this scale in Kenya.⁴⁴ Scores from PHQ-9 and GAD-7 were combined to generate a
54
55 161 variable called CMD (symptoms of common mental disorders) comorbidity, indicating the co-
56
57 162 occurrence of depressive and anxiety symptoms.

58
59 163 **Sociodemographic and asset index items:** A sociodemographic questionnaire was used to
60
164 collect information on the participants’ age, gender, relationship status, educational level,
165 employment status, and whom they currently shared a residence. Furthermore, an asset index
166 previously used in this setting⁴⁵ was used to collect information about participants’ socio-

1
2
3 167 economic status (SES) based on disposable assets owned. Participants were asked for
4
5 168 ownership of disposable items such as radio, television, refrigerator, gas, bicycle, motorcycle,
6
7 169 and car. The final SES score had seven (7) items. A total asset score is calculated, and
8
9 170 higher scores indicate a better SES. The maximum possible score for the asset index score
10
11 171 was 7. An asset index to estimate family wealth has been recommended as an alternative
12
13 172 approach to estimating SES in settings where reliable data on family income may not be
14
15 173 available.⁴⁶

16 174 **Clinical information:** Participants' data were extracted from the clinic's medical record
17
18 175 database and filled into a clinical record form. This information included participants' dates of
19
20 176 HIV-diagnosis, combination antiretroviral therapy initiation, most current combination
21
22 177 antiretroviral therapy regimen, cluster of differentiation 4 (CD4) cell count, viral load (within
23
24 178 the last one year), recent height and weight (for Body Mass Index (BMI) calculation), and data
25
26 179 on World Health Organization (WHO) clinical staging. Participants' clinical information was
27
28 180 retrieved from their clinical records after consent was granted. Patient-unique clinic numbers
29
30 181 were used to access participants' medical records. We report substantial missing participant
31
32 182 data on viral load from the database (n = 145) with no follow-up record of CD4 cell count for
33
34 183 all study participants.

34 184 **Instrument translation and cross-cultural adaptation**

35
36 185 The English version of the HSS-12 was forward translated by two independent bilingual
37
38 186 translators to Kiswahili and back-translated into English by two independent back translators
39
40 187 (oblivious of the original version). A group of Kenyan HIV researchers bilingual and fluent in
41
42 188 both Kiswahili and English and the translators had a harmonisation meeting to review the
43
44 189 content, conceptual, semantic, and idiomatic equivalence of the questionnaires to ensure the
45
46 190 cultural relevance of the HSS-12. Before conducting the formal phase of the study, fifteen
47
48 191 pretest interviews were conducted to assess instrumentation rigour and develop measures to
49
50 192 address any limitations or threats to bias and management procedures. The final version of the
51
52 193 questionnaire was obtained after the incorporation of changes emerging from pretesting.
53
54 194 Pretesting procedures have been elaborated further elsewhere.⁴⁷

55 195

55 196 **Patient and public involvement**

56
57 197 Patients were not involved in the design and conduct of this study.

58
59 198

199 **Statistical analyses**

200 **Factor structure and measurement invariance across age-groups and gender**

201 First, Confirmatory Factor Analysis (CFA) was used to examine the HIV-stigma scale's factor
202 structure. A CFA model representing the Swahili version of the HSS-12 was set up and
203 analysed with weighted least square mean and variance adjusted (WLSMV) using the lavaan⁴⁸
204 package in R statistical software⁴⁹ on all the 450 observations. The Goodness of fit was
205 assessed using the χ^2 test, Comparative Fit Index (CFI), Tucker Lewis Index (TLI), and root
206 mean square error of approximation (RMSEA). The data was expected to have a good fit to the
207 model if the χ^2 test was non-significant, CFI and TLI values were greater than 0.90, and
208 RMSEA score was lower than 0.05.⁵⁰

209 Secondly, after defining the model, Multi-Group Confirmatory Factor Analysis (MGCFAs)⁵¹
210 was used to test for measurement invariance of the HSS-12 for gender and age groups. Change
211 in CFI (Δ CFI) has been suggested as a robust statistic for testing the between-group invariance
212 of CFA models. Additionally, it has been recommended that invariance can be assumed when
213 Δ CFI is ≤ 0.01 in absolute values.⁵²

214 **Internal construct validity and convergent validity**

215 Means and standard deviations were used to evaluate the distribution of scores within the
216 subscale and among the items. Itemised means and standard deviations were expected to be
217 almost the same within the subscale, justifying item scores' aggregation into subscale scores.⁵³
218 The item-total correlation was used to evaluate internal construct validity. Each items'
219 corrected item-total correlation coefficients were calculated and expected to exceed 0.4 and
220 vary in range. Convergent validity was assessed using the Pearson correlation coefficient
221 between HSS-12, PHQ-9, and GAD-7 scores. Correlation coefficients were interpreted as small
222 (0.10–0.29), moderate (0.30–0.49), and large (0.49 and above).⁵⁴

223 **Reliability**

224 Cronbach's alpha and ordinal alpha were used to examine each subscale's internal consistency
225 and overall scores of the Swahili version of the HSS-12. Cronbach's alpha was considered
226 acceptable if greater than (>0.7).⁵⁵ The intra-class correlation coefficient (ICC) was used to
227 examine test-retest of the Swahili version of the HSS-12 by correlating scores taken at two
228 different time points (2 weeks apart)⁵⁶ using the same measure administered to the same
229 participant. ICC of 0.60 was considered marginal, 0.70 acceptable, and anything over 0.80
230 considered high.⁵⁷

231 **Sample characteristics and correlates**

232 Frequencies and means (with percentages and standard deviations) were used to describe
233 sample characteristics. Univariate and multivariable linear regression were used to assess
234 factors associated with both stigma subscales and the overall stigma scale. In the regression
235 model, stigma scores were expressed as a continuous measure. Independent variables included
236 age, gender, marital status, education level, employment status, socioeconomic status (SES),
237 body mass index (BMI), viral load, WHO clinical stages, months since HIV diagnosis, months
238 since cART initiation, HIV status disclosure, self-reported opportunistic infections, and the co-
239 occurrence of depressive and anxiety symptoms. Our review of the literature informed factors
240 included in the model. All variables with $p < 0.20$ were included in the multivariable regression
241 model apart from viral load because participants had missing values ($n = 145$). The final
242 multivariable models were generated using a backward stepwise approach by eliminating all
243 variables independently with $p > 0.05$. Assumptions of linear regression testing were visually
244 inspected through histograms (linearity), normal probability plots (normality), and plots of
245 residual versus predicted values (homoscedasticity). Multicollinearity was assessed using the
246 variance inflation factor (VIF). There were no multicollinearity problems. Modelling was
247 undertaken five times in total: once to predict overall stigma and once to predict each of the
248 four subscales. R (version 4.0.2) statistical software package⁴⁹ was used to explore the
249 construct validity of the HSS-12. All other analyses were run using (Stata version 14.0)
250 statistical software package.⁵⁸

251 **Results**

252 **Sample Characteristics**

253 The 450 participants had a median age of 43 years (IQR = 36-50), ranging from 18 to 60 years.
254 The vast majority of the sample were female (79.1%), had attained basic primary level
255 education (53.1%), lived with a family member (82.4%), and were unemployed (59.8%). Less
256 than half of the study participants (43.8%) were separated, divorced, or widowed. The mean
257 BMI was within the normal range (mean [SD] = 22.4 [4.8]). Most study participants had
258 disclosed their HIV status to others (94.0%). The median time since HIV diagnosis was 8.8
259 years (IQR = 4.67-11.50), ranging from 0 to 18 years. A total of 417 (93.7%) were in stage 1 of
260 the WHO clinical staging, and 425 (95.3%) were on the first-line cART regimen (Table 1). The
261 median time elapsed since cART initiation was 6.7 years (IQR = 3.67-10.00). At the time of
262 the interview, less than a fifth (18.4%) of the study participants had an opportunistic infection.

1
2
3 263 Perceived overall stigma scores ranged from 12 to 48, with a median score of 28 (IQR = 23-
4 264 33). Using PHQ-9 and GAD-7 cut-off score of ≥ 10 , which has been shown to maximise
5 265 specificity and sensitivity for depression⁵⁹ and general anxiety disorder⁴³ screening, the overall
6 266 prevalence of depression and anxiety was 13.8% and 5.3%, respectively, among enrolled
7 267 participants. The co-occurrence of depressive and anxiety symptoms was present in 4.7% of
8 268 the study participants.

14 269 **Factor structure and measurement invariance across age groups and gender**

16 270 Supplementary Supplementary Figure 1 presents CFA results with standardised correlation
17 271 coefficients. Our hypothesised model that the overall stigma scale comprises four sub-scales
18 272 correlated was confirmed given the observed fit indexes. The χ^2 test was statistically significant
19 273 ($\chi^2 = 91.982$, $df = 50$, $p = 0.000$) but alternate fit measures indicated acceptable fit; RMSEA:
20 274 0.044; CFI: 0.966 and TLI: 0.955. These results generally indicate that the data had a good fit
21 275 to the model and that we can confidently use both total and sub-scale scores in this population.
22 276 Measurement invariance across age groups and gender was supported because Δ CFIs are lower
23 277 than 0.01 in all models suggesting that measurement invariance can be assumed.

31 278 **Internal construct validity and convergent validity**

33 279 The factor loading of all items on the hypothesised scale was good except for item 6 (0.21)
34 280 under the disclosure concern subscale. Convergent validity of the HSS-12 was demonstrated
35 281 by the small to moderate correlations between HSS-12 and the correlation with the following
36 282 relevant measures: GAD-7 ($r = 0.368$, $p < 0.001$) and PHQ-9 ($r = 0.328$, $p < 0.001$) Table 2.

41 283 **Reliability: Internal consistency and test-retest**

43 284 Cronbach's alpha (α) for the subscales and overall scale were all > 0.7 (see Table 2) except for
44 285 the disclosure concern sub-scale, which was 0.53 (95%CI: 0.46, 0.60). Additionally, ordinal α
45 286 for the subscales ranged from 0.65-0.91. The test-retest reliability of the short 12-item version
46 287 of the HIV stigma scale was excellent, 0.92 (95%CI: 0.87, 0.95). Additionally, Table 2 presents
47 288 descriptive statistics for the stigma scale on the item level and subscale level. Corrected item-
48 289 total correlation coefficients were > 0.4 for all the items apart from one item (0.21) in the
49 290 disclosure concerns subscale. A variation of 0.46-0.88 indicates that the intended stigma
50 291 concepts' broadness had been captured.

292 **Correlates of perceived HIV-related stigma**

293 Table 3 and Table 4 present results based on univariate and multivariable regression analyses,
294 respectively. In the univariate model, it was found that being female, being separated, divorced
295 or widowed, having primary or no level of education, being self-employed or unemployed,
296 having a low asset index score, having a viral load of >1000 copies/ml, decreased duration
297 since HIV diagnosis, decreased duration since cART initiation, HIV status non-disclosure,
298 having any current opportunistic infection and co-occurrence of depression and anxiety
299 symptoms were significantly associated with overall HIV stigma scores.

300 *Personalised stigma* was significantly associated with being female, being single, separated,
301 divorced or widowed, self-employed or unemployed, having a low asset index score, having a
302 viral load of >1000 copies/ml, having any current opportunistic infection, and the co-
303 occurrence of depressive and anxiety symptoms. *Disclosure concern* was significantly
304 associated with being separated, divorced or widowed, having no level of education, having a
305 low asset index score, less time elapsed since HIV diagnosis, less time elapsed since cART
306 initiation, and HIV status non-disclosure. *Concern with public attitudes* was significantly
307 associated with being female, having primary or no level of education, decreased duration since
308 cART initiation, and the co-occurrence of depressive and anxiety symptoms. *Negative self-*
309 *image* was significantly associated with being separated, widowed or divorced, having no level
310 of education, being self-employed or unemployed, having a viral load of >1000 copies/ml,
311 decreased duration since HIV diagnosis, decreased duration since cART initiation, having any
312 current opportunistic infection and the co-occurrence of depressive and anxiety symptoms.

313 When a multiple linear regression model was run, it was found that being female ($\beta=2.001$,
314 $95\%CI: 0.21, 3.80$, $p=0.029$), HIV status disclosure ($\beta=4.237$, $95\%CI: 1.27, 7.20$, $p=0.005$)
315 and co-occurrence of depressive and anxiety symptoms ($\beta=6.670$, $95\%CI: 3.40, 9.94$, $p<0.001$)
316 were significant predictors of perceived HIV stigma. Having no education was associated with
317 increasing stigma levels at $p=0.051$ ($\beta=3.318$, $95\%CI: -.01, 6.65$). Regression results indicated
318 that the model explained 10.2% of the variance and that the model was a significant predictor
319 of perceived HIV stigma $F(6, 395) = 7.46$, $p<.001$).

320 Concerning the four subscales, we found that *personalised stigma* was positively correlated
321 with being female and the co-occurrence of depressive and anxiety symptoms. *Disclosure*
322 *concern* was inversely correlated with duration since HIV diagnosis and positively correlated
323 with having no level of education and HIV status non-disclosure. *Concerns with public*

1
2
3 324 *attitudes* were positively correlated with being female. *Negative self-image* was positively
4
5 325 correlated with having no level of education and the co-occurrence of depressive and anxiety
6
7 326 symptoms.

9 327 **Discussion**

11 328 This cross-sectional analysis of data from adults living with HIV observed that the HSS-12
12
13 329 presents excellent psychometric properties. Additionally, we observed that stigma was
14
15 330 associated with both physical and mental well-being. According to our study, correlates of
16
17 331 HIV-related stigma include being female, HIV status non-disclosure, and the co-occurrence of
18
19 332 depressive and anxiety symptoms.

21 333 **Factor structure, measurement invariance, validity and reliability of the short 12-item** 22 23 334 **Swahili version of the HIV Stigma Scale**

24 335 The study examined the stigma scale's psychometric properties to assess its usefulness and
25
26 336 describe the correlates of HIV-related stigma among adults living with HIV in Kilifi.
27
28 337 Reliability and validity were acceptable, and confirmatory factor analysis supported the four-
29
30 338 factor solution measuring the four dimensions of HIV stigma. Cronbach's alpha for the HSS-
31
32 339 12 among the Kenyan population is similar to the Swedish population in which the scale was
33
34 340 developed.¹⁴ Although Cronbach's alpha for the adapted HSS-12 sub-scales was slightly lower
35
36 341 (0.53-0.84) than the initial version of HSS-12 (0.80-0.88), its' alpha for the total scale was 0.80
37
38 342 suggesting good internal consistency. Furthermore, the adapted HSS-12 had an ordinal alpha
39
40 343 of 0.86. The difference between ordinal alpha and Cronbach's alpha values could be attributed
41
42 344 to high skewness and kurtosis values for some of the questionnaire's questions, influencing
43
44 345 Cronbach's alpha estimate values.^{60 61}

44 346 Measurement invariance of the Swahili HSS-12 was evaluated and confirmed across main
45
46 347 interest groups: gender and age. Our results indicated that the measurement model of the
47
48 348 Swahili HSS-12 as a patient-reported outcome to measure perceived HIV stigma among adults
49
50 349 is comparable across age groups and gender (Table 5).

51 350 Test-retest reliability, an indicator of scale stability over time, was of acceptable levels. The
52
53 351 original HSS-40 has been used in diverse settings^{13 62} among adults 18 years and above,
54
55 352 reporting a test re-test reliability between (ICC=0.89-0.92). To the best of our knowledge, no
56
57 353 study has reported the test re-test reliability of the HSS-12.

1
2
3 354 We examined the construct validity of the scale using CFA since its hypothesised structure has
4
5 355 been published.¹⁴ Our results indicated that the hypothesised model fit the data well and was
6
7 356 almost similar to what was reported by a study conducted in Sweden.¹⁴ These results indicate
8
9 357 that one can use both the total scores and the subscale scores and interpret the results in
10
11 358 confidence, knowing that the items fit well together. HSS-12 evidenced convergent validity by
12
13 359 being correlated with PHQ-9, a measure of depression, and GAD-7, a measure of anxiety in
14
15 360 conventional ways.

16 361 The HSS-12 was reliable and valid for detecting stigma among adults living with HIV at the
17
18 362 Kenyan Coast. Consequently, HSS-12 can be practically used as a brief screening tool for
19
20 363 stigma-related problems both for research and clinical purposes. Future research could examine
21
22 364 its predictive validity and evaluate its sensitivity to changes. This information would be crucial
23
24 365 in determining its usefulness as an evaluation tool for programmes and interventions.

25 366 **Correlates of Stigma**

26
27 367 Being female was positively associated with increased perceived HIV-related stigma scores,
28
29 368 *personalised stigma*, and *concern with public attitudes*. This finding agrees with previous
30
31 369 studies from SSA⁶³ and outside^{64 28} that reported a positive association between female gender
32
33 370 and perceived HIV-related stigma. Research shows that females are more likely to suffer from
34
35 371 stigma in patriarchal societies like Kenya than males.^{65 66} Research has established that the
36
37 372 African society is less tolerant of females living with HIV than males living with HIV.^{67 68} Due
38
39 373 to women's subordinate status in society, they are often stigmatised as vectors of
40
41 374 transmission.⁶⁹ Furthermore, the common belief that HIV is caused by indecent sexual
42
43 375 behaviour has worse societal consequences for women who are expected to be monogamous,
44
45 376 unlike men in most African societies.⁶⁷ Women are often blamed counterfactually to be
46
47 377 responsible for HIV transmission.⁶⁷ Similar processes can be assumed to be at work in the
48
49 378 Kenyan coastal region.

50
51 379 HIV status disclosure was positively associated with overall HIV-related stigma scores and
52
53 380 *disclosure concerns*, with persons who had not disclosed their HIV status reporting greater
54
55 381 levels of concern about HIV disclosure concerns. Anakwa and colleagues found that PLWHA
56
57 382 with higher levels of perceived HIV-related stigma reported greater levels of HIV disclosure
58
59 383 concerns; therefore, they are less likely to disclose their status.³⁴ From our study, only 6% had
60
384 not disclosed their status to anyone. HIV status non-disclosure might be a protective behaviour
385 for PLWHA to conceal their status, evade adverse reactions towards themselves, weigh other

1
2
3 386 people's reactions, and as a sign of concern about the implication of their disclosure on their
4
5 387 disclosure targets.^{70 71} Furthermore, disclosure entails deciding how and to whom to disclose
6
7 388 and identifying appropriate opportunities to disclose or devising means to conceal ones' status
8
9 389 and/or medication in order to improve access and adherence to their treatment regimen.

10
11 390 The co-occurrence of depressive and anxiety symptoms was positively correlated with overall
12
13 391 HIV-related stigma scores, *personalised stigma*, and *negative self-image*. This finding
14
15 392 corroborates previous studies among PLWHA carried out within SSA,^{30 72, 26} and outside,^{73 74}
16
17 393 which have invariably found a significant association between HIV-related stigma and
18
19 394 depressive symptoms. Liu and colleagues⁷⁵ reported that the more stigma PLWHA perceived,
20
21 395 the more anxiety they experienced. Similarly, we report that HIV-related stigma is significantly
22
23 396 associated with the co-occurrence of depressive and anxiety symptoms. Additionally, an
24
25 397 individual's perception of themselves in light of their diagnosis appears to trigger depression.⁷⁶
26
27 398 Screening for depression, anxiety, and HIV-related stigma might provide insights on
28
29 399 interventions that may promote a positive attitude and self-image, thereby reducing depression,
30
31 400 anxiety, and stigma, leading to psychological and physical well-being. Given the cross-
32
33 401 sectional nature of the study, we cannot claim causality. However, the association between co-
34
35 402 occurrence of depressive and anxiety symptoms and stigma provides the impetus for: a)
36
37 403 longitudinal studies to elucidate causal pathways; and b) targeted interventions to address both
38
39 404 stigma and mental health to improve health outcomes of adults living with HIV.

40
41 405 Other factors influencing the four subscales were also established. Having no level of education
42
43 406 was positively associated with higher reported *disclosure concerns* and *negative self-image*,
44
45 407 corroborating findings of studies carried out in Nigeria⁷⁷ and the USA.⁷⁸ Lower levels of
46
47 408 education may lead to less exposure, lack of or little knowledge about HIV infection and
48
49 409 transmission. In contrast, higher levels of education might lead to higher levels of knowledge,
50
51 410 providing exposure to new ways of thinking and new sources of information about the HIV
52
53 411 pandemic resulting in the reduction of less supportive attitudes towards PLWHA.^{79 80} Previous
54
55 412 research has demonstrated that people with high levels of knowledge of the transmission routes
56
57 413 for HIV consistently had more supportive attitudes towards those with HIV demonstrating the
58
59 414 role that knowledge has in reducing the misconceptions that act to create fear and shape
60
415 stigma.⁷⁹

416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

416 Months since HIV diagnosis was inversely associated with *disclosure concerns*, with persons
417 with a more recent diagnosis reporting greater levels of concern about HIV status disclosure.

1
2
3 418 This is consistent with a study of people living with HIV/AIDS (PLWHA) in China⁸¹ and
4
5 419 among African Americans.⁷⁸ This finding suggests that living longer with HIV is associated
6
7 420 with positive outcomes because PLWHA are likely to adjust over time to their HIV positive
8
9 421 status, receive more information, develop greater insights and understanding of the disease and
10
11 422 establish psychological mechanisms to better cope with HIV stigma leading to lower levels of
12
13 423 perceived HIV stigma.

14 424 **Strengths and limitations of this study**

15
16 425 A potential strength is that this is the first study to report the measurement characteristics of
17
18 426 the 12-item HIV stigma scale in the SSA context. We recognise several potential limitations in
19
20 427 this study. First, the study was in a clinical setting where our study sample consisted of adults
21
22 428 living with HIV on cART. Compared to untreated individuals living with HIV, it is likely that
23
24 429 levels of HIV stigma would be lower in our sample because it has been shown that access to
25
26 430 ART lowers stigma.⁸²⁻⁸⁴ Second, this study is cross-sectional, so causality for the observed
27
28 431 significant associations cannot be inferred. We can also not conclude how individuals may
29
30 432 experience stigma over time because of the study design limitation. Third, findings may not be
31
32 433 generalisable to all adults living with HIV in Kenya as data were collected from one
33
34 434 geographical setting and excluded adults older than 60 years. Fourth, because many
35
36 435 participants (n = 145) lacked information on their most recent viral load and none had follow-
37
38 436 up data on CD4 counts, these variables were excluded from the regression analyses. A
39
40 437 disproportionately large number of patients, combined with financial constraints, may explain
41
42 438 why these tests are not routinely performed. Future studies, particularly those from resource-
43
44 439 constrained settings, should budget for these tests because these biological factors have been
45
46 440 associated with HIV-related stigma.⁸⁵ Finally, the psychometric robustness of the disclosure
47
48 441 concern sub-scale may be limited. We recommend further research into investigating this
49
50 442 specific subscale.

51 443 **Conclusions and implications**

52
53 444 From the study, the 12-item short version of the Berger HIV stigma scale¹⁴ had good
54
55 445 psychometric properties and can be recommended for research purposes. The current study
56
57 446 suggests that women, those who have not disclosed, and those experiencing co-occurring
58
59 447 depressive and anxiety symptoms experience a higher level of perceived HIV stigma in Coastal
60
448 Kenya. This finding is useful in designing future interventions to improve the quality of life of
449
450 449 people living with HIV/AIDS. We propose interventions that need to take into account gender

1
2
3 450 to address the specific needs of women, people who have not disclosed their HIV status, and
4
5 451 those exhibiting symptoms of depression and anxiety, thereby improving their quality of life.
6
7 452 All these interventions will help in bettering both the physical and mental well-being of adults
8
9 453 living with HIV. Additionally, it would be prudent to investigate further the association
10
11 454 between lower education and HIV-related stigma as we found a marginal association.
12

13 455 **Acknowledgements**

14
15 456 We thank our participants for taking the time and effort to participate in this study and the
16
17 457 Comprehensive Care and Research Centre (CCRC) staff in the Kilifi County Hospital HIV care
18
19 458 and treatment clinic for their unrelenting support. We appreciate Patrick Katana Vidzo for
20
21 459 helping with the entry of clinical data. The authors acknowledge the Kenya Medical Research
22
23 460 Institute (KEMRI) Director for permission to publish this work.
24

25 461 **Footnotes**

26
27 462 *Author Contributions:* SWW, CN, and AA conceptualised the study. SWW, MKN and AA
28
29 463 designed the study. PM formulated study questions for tablet administration and managed the
30
31 464 data. SWW and MKN supervised data collection. SWW, MKN, and AM participated in data
32
33 465 collection. SWW and MKN analysed the data. SWW, MKN, PM, AM, SL, CN and AA
34
35 466 contributed to interpreting the data. SWW wrote the first draft of the manuscript. All authors
36
37 467 reviewed subsequent versions of the manuscript and approved the final version for submission.
38
39 468 The corresponding author affirms that all listed authors meet authorship criteria and that no
40
41 469 other author meeting the criteria has been omitted.
42

43 471 *Funding:* This work was supported by funding from the Medical Research Council (Grant
44
45 472 number MR/M025454/1) to AA. This award is jointly funded by the UK Medical Research
46
47 473 Council (MRC) and the UK Department for International Development (DFID) under the
48
49 474 MRC/DFID concordant agreement and is also part of the EDCTP2 program supported by the
50
51 475 European Union.
52

53 477 *Disclaimer:* The funders had no role in the design, collection, analysis, interpretation and
54
55 478 manuscript writing.
56

57 479

58 480 *Competing interests:* None declared.
59
60

1
2
3 481

482 *Ethical approval:* The local institutional review board, Scientific and Ethics Review Board
483 (SERU; Ref KEMRI/SERU/CGMR-C/108/3594), granted ethical approval to recruit
484 participants into the study. We obtained authorisation to work in the HIV care and treatment
485 clinic from the Ministry of Health, County government of Kilifi (Ref HP/KCHS/VOL.VIX/65).
486 Study participants provided written, informed consent to be part of the study.

13 487

488 *Transparency:* The lead author (SWW) confirms that the manuscript is an honest, accurate,
489 and sincere account of the research being reported; no important aspects of the research have
490 been omitted; and that explanations for any discrepancies from the research as planned (and, if
491 relevant, registered) have been provided.

22 492

493 *Data sharing statement:* No additional data are available. Anyone interested in accessing the
494 data reported in this article is free to write to the Data Governance Committee of the KEMRI
495 Wellcome Trust Research Programme, review the application and advise as appropriate, and
496 ensure that uses are compatible with the consent obtained from participants for data collection.
497 Requests can be sent to the coordinator of the Data Governance Committee using the following
498 email: dgc@kemri-wellcome.org.

499 REFERENCES

- 500 1. Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics — 2020
501 fact sheet [Available from: <https://www.unaids.org/en/resources/fact-sheet> accessed
502 22/2/2021].
- 503 2. Joint United Nations Programme on HIV/AIDS. UNAIDS DATA 2020. Switzerland:
504 UNAIDS; 2020. Available from:
505 https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf
506 [Accessed 8/9/2021]
- 507 3. National AIDS Control Council (NACC). Kenya AIDS Response Progress Report 2014:
508 Progress towards Zero. Nairobi, Kenya: National AIDS Control Council of Kenya;
509 2014. Available from:
510 https://www.unaids.org/sites/default/files/country/documents/KEN_narrative_report_2014.pdf
511 [Accessed 04/06/2020]
- 512 4. Goffman E. Stigma. Notes on the Management of Spoiled Identity. New York: Simon and
513 Shuster: Inc, 1963.
- 514 5. Jones EE, Farina A, Hastorf AH, et al. Social stigma: the psychology of marked
515 relationships. New York: W.H. Freeman 1984.
- 516 6. Maluccio JA, Wu F, Rokon RB, et al. Assessing the Impact of Food Assistance on Stigma
517 Among People Living with HIV in Uganda Using the HIV/AIDS Stigma Instrument-
518 PLWA (HASI-P). *Aids Behav* 2017;21(3):766-82. doi: 10.1007/s10461-016-1476-9
519 [published Online First: 2016/07/04]
- 520 7. Dahlui M, Azahar N, Bulgiba A, et al. HIV/AIDS Related Stigma and Discrimination
521 against PLWHA in Nigerian Population. *PLoS One* 2015;10(12):e0143749. doi:
522 10.1371/journal.pone.0143749 [published Online First: 2015/12/15]
- 523 8. Toth S, J AY, DePinto N. HIV stigma: perceptions from HIV-positive and HIV-negative
524 patients in a community dental clinic. *Journal of dental research, dental clinics,*
525 *dental prospects* 2016;10(4):263-69. doi: 10.15171/joddd.2016.042 [published Online
526 First: 2017/01/18]
- 527 9. Nyblade L, Stangl A, Weiss E, et al. Combating HIV stigma in health care settings: what
528 works? *J Int AIDS Soc* 2009;12:15. doi: 10.1186/1758-2652-12-15 [published Online
529 First: 2009/08/08]
- 530 10. Clark HJ, Lindner G, Armistead L, et al. Stigma, disclosure, and psychological
531 functioning among HIV-infected and non-infected African-American women. *Women*
532 *& health* 2004;38(4):57-71.
- 533 11. Lindberg MH, Wettergren L, Wiklander M, et al. Psychometric evaluation of the HIV
534 stigma scale in a Swedish context. *PLoS One* 2014;9(12):e114867. doi:
535 10.1371/journal.pone.0114867 [published Online First: 2014/12/19]
- 536 12. Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of
537 HIV stigma mechanism measures. *Aids Behav* 2009;13(6):1160-77. doi:
538 10.1007/s10461-009-9593-3 [published Online First: 2009/07/29]
- 539 13. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric
540 assessment of the HIV stigma scale. *Research in nursing & health* 2001;24(6):518-29.
541 doi: doi.org/10.1002/nur.10011
- 542 14. Reinius M, Wettergren L, Wiklander M, et al. Development of a 12-item short version of
543 the HIV stigma scale. *Health and Quality of Life Outcomes* 2017;15(1):115. doi:
544 10.1186/s12955-017-0691-z [published Online First: 2017/06/01]
- 545 15. Kingori C, Reece M, Obeng S, et al. Psychometric evaluation of a cross-culturally
546 adapted felt stigma questionnaire among people living with HIV in Kenya. *Aids*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 547 *Patient Care St* 2013;27(8):481-8. doi: 10.1089/apc.2012.0403 [published Online
548 First: 2013/08/24]
- 549 16. Wiklander M, Rydstrom LL, Ygge BM, et al. Psychometric properties of a short version
550 of the HIV stigma scale, adapted for children with HIV infection. *Health Qual Life*
551 *Outcomes* 2013;11(1):195. doi: 10.1186/1477-7525-11-195 [published Online First:
552 2013/11/15]
- 553 17. Holzemer WL, Uys LR, Chirwa ML, et al. Validation of the HIV/AIDS Stigma
554 Instrument—PLWA (HASI-P). 2007;19(8):1002-12.
- 555 18. Bauman L, Silver E, Camacho S Stigma among mothers with HIV/AIDS. XIII
556 International AIDS Conference, Durban, South Africa; 2000
- 557 19. Fife BL, Wright ER. The dimensionality of stigma: a comparison of its impact on the self
558 of persons with HIV/AIDS and cancer. *J Health Soc Behav* 2000;41(1):50-67.
559 [published Online First: 2000/04/06]
- 560 20. Herek GM, Capitanio JP. Public reactions to AIDS in the United States: a second decade
561 of stigma. *Am J Public Health* 1993;83(4):574-7. doi: 10.2105/ajph.83.4.574
562 [published Online First: 1993/04/01]
- 563 21. Sowell RL, Seals BF, Moneyham L, et al. Quality of life in HIV-infected women in the
564 south-eastern United States. *AIDS Care* 1997;9(5):501-12. doi: 10.1080/713613191
565 [published Online First: 1997/12/24]
- 566 22. Jeyaseelan L, Kumar S, Mohanraj R, et al. Assessing HIV/AIDS stigma in South India:
567 validation and abridgement of the Berger HIV stigma scale. 2013;17(1):434-43.
- 568 23. Bunn JY, Solomon SE, Miller C, et al. Measurement of stigma in people with HIV: a
569 reexamination of the HIV Stigma Scale. *AIDS Educ Prev* 2007;19(3):198-208. doi:
570 10.1521/aeap.2007.19.3.198 [published Online First: 2007/06/15]
- 571 24. Emlert CA, Brennan DJ, Brennenstuhl S, et al. The impact of HIV-related stigma on older
572 and younger adults living with HIV disease: does age matter? *AIDS care*
573 2015;27(4):520-28.
- 574 25. Pannetier J, Lelievre E, Le Coeur S. HIV-related stigma experiences: Understanding
575 gender disparities in Thailand. *AIDS Care* 2016;28(2):170-8. doi:
576 10.1080/09540121.2015.1096888 [published Online First: 2015/10/20]
- 577 26. Endeshaw M, Walson J, Rawlins S, et al. Stigma in Ethiopia: association with depressive
578 symptoms in people with HIV. *AIDS Care* 2014;26(8):935-9. doi:
579 10.1080/09540121.2013.869537 [published Online First: 2014/01/03]
- 580 27. Datta S, Bhattacharjee S, Sherpa PL, et al. Perceived HIV Related Stigma among Patients
581 Attending ART Center of a Tertiary Care Center in Rural West Bengal, India. *J Clin*
582 *Diagn Res* 2016;10(10):VC09-VC12. doi: 10.7860/JCDR/2016/21366.8669
583 [published Online First: 2016/11/29]
- 584 28. Sorsdahl KR, Mall S, Stein DJ, et al. The prevalence and predictors of stigma amongst
585 people living with HIV/AIDS in the Western Province. *AIDS Care* 2011;23(6):680-5.
586 doi: 10.1080/09540121.2010.525621 [published Online First: 2011/03/02]
- 587 29. Yeo TED, Chu TH. Social-cultural factors of HIV-related stigma among the Chinese
588 general population in Hong Kong. *AIDS Care* 2017;29(10):1255-59. doi:
589 10.1080/09540121.2017.1282601 [published Online First: 2017/01/24]
- 590 30. Cuca YP, Onono M, Bukusi E, et al. Factors associated with pregnant women's
591 anticipations and experiences of HIV-related stigma in rural Kenya. *AIDS Care*
592 2012;24(9):1173-80. doi: 10.1080/09540121.2012.699669 [published Online First:
593 2012/07/18]
- 594 31. Girma E, Gebretsadik LA, Kaufman MR, et al. Stigma against people with HIV/AIDS in
595 rural Ethiopia, 2005 to 2011: signs and predictors of improvement. *Aids Behav*

- 1
2
3 596 2014;18(6):1046-53. doi: 10.1007/s10461-013-0611-0 [published Online First:
4 597 2013/09/28]
- 5 598 32. Takada S, Weiser SD, Kumbakumba E, et al. The Dynamic Relationship Between Social
6 599 Support and HIV-Related Stigma in Rural Uganda. *Ann Behav Med* 2014;48(1):26-
7 600 37. doi: 10.1007/s12160-013-9576-5
- 8 601 33. Emlert CA. A comparison of HIV stigma and disclosure patterns between older and
9 602 younger adults living with HIV/AIDS. *Aids Patient Care and Stds* 2006;20(5):350-58.
10 603 doi: DOI 10.1089/apc.2006.20.350
- 11 604 34. Anakwa NO, Teye-Kwadjo E, Kretchy IA. Effect of HIV-Related Stigma and HIV-
12 605 Related Stress on HIV Disclosure Concerns: a Study of HIV-Positive Persons on
13 606 Antiretroviral Therapy at Two Urban Hospitals in Ghana. *Applied Research in*
14 607 *Quality of Life* 2020:1-16.
- 15 608 35. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic
16 609 Surveillance System (KHDSS). *Int J Epidemiol* 2012;41(3):650-7. doi:
17 610 10.1093/ije/dys062 [published Online First: 2012/05/01]
- 18 611 36. Ngugi E, Kipruto S, Samoei P. Exploring Kenya's Inequality: Pulling Apart or Pooling
19 612 Together? Kilifi County. Nairobi, Kenya: Kenya National Bureau of Statistics
20 613 (KNBS) and the Society for International Development (SID) 2013.
- 21 614 37. Commission on Revenue Allocation (CRA). Kenya County Fact sheets: ; 2011 [Available
22 615 from: [http://siteresources.worldbank.org/INTAFRICA/Resources/257994-
23 616 1335471959878/Kenya_County_Fact_Sheets_Dec2011.pdf](http://siteresources.worldbank.org/INTAFRICA/Resources/257994-1335471959878/Kenya_County_Fact_Sheets_Dec2011.pdf) accessed 22nd August
24 617 2018.
- 25 618 38. National AIDS Control Council. Kenya HIV County Profiles - 2016: National AIDS
26 619 Control Council; 2016 [49-52]. Available from: [http://nacc.or.ke/wp-
27 620 content/uploads/2016/12/Kenya-HIV-County-Profiles-2016.pdf](http://nacc.or.ke/wp-content/uploads/2016/12/Kenya-HIV-County-Profiles-2016.pdf) accessed 20th August
28 621 2018.
- 29 622 39. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
30 623 community of software platform partners. 2019;95:103208.
- 31 624 40. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a
32 625 metadata-driven methodology and workflow process for providing translational
33 626 research informatics support. 2009;42(2):377-81.
- 34 627 41. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of
35 628 PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental
36 629 Disorders. Patient Health Questionnaire. *JAMA* 1999;282(18):1737-44. doi:
37 630 10.1001/jama.282.18.1737 [published Online First: 1999/11/24]
- 38 631 42. Monahan PO, Shacham E, Reece M, et al. Validity/reliability of PHQ-9 and PHQ-2
39 632 depression scales among adults living with HIV/AIDS in western Kenya. *J Gen Intern*
40 633 *Med* 2009;24(2):189-97. doi: 10.1007/s11606-008-0846-z [published Online First:
41 634 2008/11/26]
- 42 635 43. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized
43 636 anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092-7. doi:
44 637 10.1001/archinte.166.10.1092 [published Online First: 2006/05/24]
- 45 638 44. Osborn TL, Venturo-Conerly KE, Wasil AR, et al. Depression and anxiety symptoms,
46 639 social support, and demographic factors among Kenyan high school students. *Journal*
47 640 *of Child Family Studies* 2019:1-12.
- 48 641 45. Nyongesa MK, Mwangala PN, Mwangi P, et al. Neurocognitive and mental health
49 642 outcomes and association with quality of life among adults living with HIV: a cross-
50 643 sectional focus on a low-literacy population from coastal Kenya. *Bmj Open*
51 644 2018;8(9):e023914. doi: 10.1136/bmjopen-2018-023914 [published Online First:
52 645 2018/09/19]

- 1
2
3 646 46. Filmer D, Pritchett LHJD. Estimating wealth effects without expenditure data—or tears:
4 647 an application to educational enrollments in states of India. *%J Demography*
5 648 2001;38(1):115-32.
- 6 649 47. Nyongesa MK, Mwangi P, Wanjala SW, et al. Correlates of health-related quality of life
7 650 among adults receiving combination antiretroviral therapy in coastal Kenya. *Health*
8 651 *quality of life outcomes* 2020;18:1-14. doi: 10.1186/s12955-020-01421-0
- 9 652 48. Rosseel Y. Lavaan: An R package for structural equation modeling and more. Version
10 653 0.5–12 (BETA). *Journal of statistical software* 2012;48(2):1-36.
- 11 654 49. R Core Team. R: A language and environment for statistical computing. R Foundation for
12 655 Statistical Computing. [computer program] 4.0.2 Vienna, Austria. 2020.
- 13 656 50. Blunch N. Introduction to structural equation modeling using IBM SPSS statistics and
14 657 AMOS: Sage 2012.
- 15 658 51. Van de Schoot R, Lugtig P, Hox J. A checklist for testing measurement invariance.
16 659 *European Journal of Developmental Psychology* 2012;9(4):486-92.
- 17 660 52. Cheung GW, Rensvold RB. Assessing extreme and acquiescence response sets in cross-
18 661 cultural research using structural equations modeling. *Journal of cross-cultural*
19 662 *psychology* 2000;31(2):187-212.
- 20 663 53. Ware Jr JE, Gandek B, Joce. Methods for testing data quality, scaling assumptions, and
21 664 reliability: the IQOLA Project approach. 1998;51(11):945-52.
- 22 665 54. Cohen J. Statistical power analysis for the behavioural sciences, 2nd edn.(Hillsdale, NJ:
23 666 L. Erlbaum Associates). 1988
- 24 667 55. Tabachnik B, Fidell L. Using multivariate statistics (6e éd.). Boston, É.-U. U: *Pearson*
25 668 2013
- 26 669 56. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement
27 670 properties of health status questionnaires. *Journal of clinical epidemiology*
28 671 2007;60(1):34-42. doi: 10.1016/j.jclinepi.2006.03.012
- 29 672 57. Streiner DL. A checklist for evaluating the usefulness of rating scales. *Canadian journal*
30 673 *of psychiatry Revue canadienne de psychiatrie* 1993;38(2):140-8. doi:
31 674 10.1177/070674379303800214 [published Online First: 1993/03/01]
- 32 675 58. StataCorp LP. Stata statistical software: release 14. [computer program] College Station,
33 676 TX; StataCorp LP: 2015.
- 34 677 59. Akena D, Joska J, Obuku EA, et al. Sensitivity and specificity of clinician administered
35 678 screening instruments in detecting depression among HIV-positive individuals in
36 679 Uganda. *AIDS Care* 2013;25(10):1245-52. doi: 10.1080/09540121.2013.764385
37 680 [published Online First: 2013/02/13]
- 38 681 60. Gadermann A, Guhn M, Zumbo B. Estimating ordinal reliability for Likert-type and
39 682 ordinal item response data: A conceptual, empirical, and practical guide. *P Ass, Re &*
40 683 *Evalu*, 17 (3), 1-13, 2012.
- 41 684 61. González J, Pazmiño MJRP. Cálculo e interpretación del Alfa de Cálculo e interpretación
42 685 del Alfa de Cronbach para el caso de validación de la consistencia interna de un
43 686 cuestionario, con dos posibles escalas tipo Likert. 2015;2(1):62-77.
- 44 687 62. Jeyaseelan L, Kumar S, Mohanraj R, et al. Assessing HIV/AIDS stigma in south India:
45 688 validation and abridgement of the Berger HIV Stigma scale. *Aids Behav*
46 689 2013;17(1):434-43. doi: 10.1007/s10461-011-0128-3 [published Online First:
47 690 2012/01/17]
- 48 691 63. Nattabi B, Li J, Thompson SC, et al. Factors associated with perceived stigma among
49 692 people living with HIV/AIDS in post-conflict northern Uganda. *AIDS Education and*
50 693 *Prevention* 2011;23(3):193-205.

- 1
2
3 694 64. Swendeman D, Rotheram-Borus MJ, Comulada S, et al. Predictors of HIV-related stigma
4 695 among young people living with HIV. *Health Psychol* 2006;25(4):501-9. doi:
5 696 10.1037/0278-6133.25.4.501 [published Online First: 2006/07/19]
6 697 65. Asiedu GB, Myers-Bowman KS. Gender differences in the experiences of HIV/AIDS-
7 698 related stigma: a qualitative study in Ghana. *Health Care Women Int* 2014;35(7-
8 699 9):703-27. doi: 10.1080/07399332.2014.895367 [published Online First: 2014/02/26]
9 700 66. Mugoya GC, Ernst K. Gender differences in HIV-related stigma in Kenya. *AIDS Care*
10 701 2014;26(2):206-13. doi: 10.1080/09540121.2013.808733 [published Online First:
11 702 2013/06/26]
12 703 67. Mbonu NC, van den Borne B, De Vries NK. Stigma of People with HIV/AIDS in Sub-
13 704 Saharan Africa: A Literature Review. *J Trop Med* 2009;2009:145891. doi:
14 705 10.1155/2009/145891 [published Online First: 2009/01/01]
15 706 68. Amuyunzu-Nyamongo M, Okeng'o L, Wagura A, et al. Putting on a brave face: the
16 707 experiences of women living with HIV and AIDS in informal settlements of Nairobi,
17 708 Kenya. *AIDS Care* 2007;19 Suppl 1(sup1):S25-34. doi: 10.1080/09540120601114618
18 709 [published Online First: 2007/03/17]
19 710 69. Muyinda H, Seeley J, Pickering H, et al. Social aspects of AIDS-related stigma in rural
20 711 Uganda. 1997;3(3):143-47.
21 712 70. Linda P. To tell or not to tell: negotiating disclosure for people living with HIV on
22 713 antiretroviral treatment in a South African setting. *SAHARA J* 2013;10 Suppl
23 714 1(sup1):S17-27. doi: 10.1080/02664763.2012.755320 [published Online First:
24 715 2013/07/17]
25 716 71. Evangeli M, Wroe AL. HIV Disclosure Anxiety: A Systematic Review and Theoretical
26 717 Synthesis. *Aids Behav* 2017;21(1):1-11. doi: 10.1007/s10461-016-1453-3 [published
27 718 Online First: 2016/07/14]
28 719 72. Nyongesa MK, Mwangi P, Wanjala SW, et al. Prevalence and correlates of depressive
29 720 symptoms among adults living with HIV in rural Kilifi, Kenya. *BMC Psychiatry*
30 721 2019;19(1):333. doi: 10.1186/s12888-019-2339-5 [published Online First:
31 722 2019/11/05]
32 723 73. Charles B, Jeyaseelan L, Pandian AK, et al. Association between stigma, depression and
33 724 quality of life of people living with HIV/AIDS (PLHA) in South India—a community
34 725 based cross sectional study. 2012;12(1):463.
35 726 74. Yi S, Chhoun P, Suong S, et al. AIDS-related stigma and mental disorders among people
36 727 living with HIV: a cross-sectional study in Cambodia. 2015;10(3):e0121461.
37 728 75. Liu Y, Gong H, Yang G, et al. Perceived stigma, mental health and unsafe sexual
38 729 behaviors of people living with HIV/AIDS. 2014;39(7):658-63.
39 730 76. Onyebuchi-Iwudibia O, Brown A. HIV and depression in Eastern Nigeria: the role of
40 731 HIV-related stigma. *AIDS Care* 2014;26(5):653-7. doi:
41 732 10.1080/09540121.2013.844761 [published Online First: 2013/10/19]
42 733 77. Oke OO, Akinboro AO, Olanrewaju FO, et al. Assessment of HIV-related stigma and
43 734 determinants among people living with HIV/AIDS in Abeokuta, Nigeria: A cross-
44 735 sectional study. *SAGE Open Medicine* 2019;7:2050312119869109.
45 736 78. Galvan FH, Davis EM, Banks D, et al. HIV stigma and social support among African
46 737 Americans. 2008;22(5):423-36.
47 738 79. Stephenson R. Community factors shaping HIV-related stigma among young people in
48 739 three African countries. *AIDS care* 2009;21(4):403-10.
49 740 80. Cianelli R, Villlegas N, De Oliveira G, et al. Predictors of HIV enacted stigma among
50 741 Chilean women. 2015;24(17-18):2392-401.
51 742 81. Li Z, Morano JP, Khoshnood K, et al. HIV-related stigma among people living with
52 743 HIV/AIDS in rural Central China. 2018;18(1):453.

- 1
2
3 744 82. Chan BT, Tsai AC, Siedner MJ. HIV Treatment Scale-Up and HIV-Related Stigma in
4 745 Sub-Saharan Africa: A Longitudinal Cross-Country Analysis. *Am J Public Health*
5 746 2015;105(8):1581-7. doi: 10.2105/AJPH.2015.302716 [published Online First:
6 747 2015/06/13]
- 7 748 83. Wolfe WR, Weiser SD, Leiter K, et al. The impact of universal access to antiretroviral
8 749 therapy on HIV stigma in Botswana. *Am J Public Health* 2008;98(10):1865-71. doi:
9 750 10.2105/AJPH.2007.122044 [published Online First: 2008/08/16]
- 10 751 84. Jurgensen M, Sandoy IF, Michelo C, et al. Effects of home-based voluntary counselling
11 752 and testing on HIV-related stigma: findings from a cluster-randomized trial in
12 753 Zambia. *Soc Sci Med* 2013;81:18-25. doi: 10.1016/j.socscimed.2013.01.011
13 754 [published Online First: 2013/02/21]
- 14 755 85. Kemp CG, Lipira LL, David H, et al. HIV stigma and viral load among African-American
15 756 women receiving treatment for HIV: A longitudinal analysis. 2019;33(9):1511.
16
17
18
19 757

758 *Table 1: Participant's sociodemographic characteristics*

Sample Characteristics	N=450	Total sample %
Sociodemographic characteristics		
Age – years Range (18-60), Median (IQR)	43(14)	
Gender		
Female	356	79.1
Male	94	20.9
Marital Status		
Married/cohabiting	196	43.6
Separated /Divorced/Widowed	197	43.8
Single/Never Married	57	12.7
Education		
Tertiary	22	4.9
Secondary	66	14.7
Primary	239	53.1
None	123	27.3
Employment		
Formally employed	53	11.8
Self-employed	117	26.0
Other	11	2.4
Unemployed (including students)	269	59.8
Currently living with		
Family	371	82.4
Relative/friend	10	2.2
Alone	69	15.3
Asset index score ^a – mean (SD)	1.2(1.4)	1.4
Perceived HIV-stigma score ^b – mean (SD)	28.4(7.7)	7.7
Any current chronic illness		
No	413	91.8
Yes	37	8.2
Clinical characteristics		
BMI – kg/m ² , mean (SD), OM = 4	22.4 (4.8)	
cART regimen, OM = 4		
First-line	425	95.3
Second line	21	4.7
Viral load, OM = 145		
≤ 1000 copies/mL	265	86.9
> 1000 copies/mL	40	13.1
WHO clinical stage, OM = 5		
Stage 1	417	93.7
Stage 2	22	4.9
Stage 3	3	0.7
Stage 4	3	0.7
Months since HIV diagnosis – Median (IQR)	106 (82)	
Months since cART initiation – Median (IQR)	80.5 (76)	
Treatment Characteristics		
HIV status disclosure		
Yes	423	94.0
No	27	6.0
Any current opportunistic infection		
No	367	81.6
Yes	83	18.4
Notes: OM = Observation with missing value, SD = Standard deviation, a - score range = 0 to 7, b – score range = 12 to 48, IQR = Interquartile range		

759

Table 2: Descriptive statistics for items and subscales in the short form 12-item Swahili version of the HIV Stigma Scale

Item	Mean item score ^a (SD)	Corrected item correlation	Mean subscale score ^b (SD)	Reliability		Validity		Construct		
				Internal consistency (Cronbach α)	Test-Retest (ICC)	\neq	#	CFI	RMSEA	TLI
Personalised Stigma			4.86(2.56)	0.84 (95% CI; 0.81-0.86)	0.83 (95% CI; 0.71-0.90)	0.357**	0.327**			
Some people stop touching me soon they know/realise I am infected with HIV/AIDS	1.66(1.01)	0.65								
People I care for stopped calling me after knowing I suffer from AIDs.	1.63(1.00)	0.87								
I have lost friends for telling/explaining that I have AIDs.	1.59(0.96)	0.88								
Disclosure Concerns			8.74(2.37)	0.53 (95% CI; 0.45-0.60)	0.62 (95% CI; 0.36-0.77)	0.070	0.070			
Telling someone that I have AIDs is dangerous*	2.24(1.24)	0.83								
I do all I can to keep my AIDs (HIV) status secret	2.90(1.22)	0.46								
I am very careful to that person I tell about my HIV status (I am cautious/ very careful to (?of) the people I tell my HIV status)	3.60(0.78)	0.21								
Concerns about Public Attitudes			8.52(3.17)	0.83 (95% CI; 0.80-0.86)	0.79 (95% CI; 0.65-0.88)	0.187**	0.165**			
People who are suffering from AIDs are treated as if they are not like the other people.	3.05(1.18)	0.68								
People believe that a person infected with HIV is dirty.	2.74(1.26)	0.84								
Many people are worried when they are near a person infected with HIV.	2.75(1.22)	0.84								
Negative Self Image			6.32(3.00)	0.74 (95% CI; 0.70-0.80)	0.76 (95% CI; 0.60-0.86)	0.372**	0.330**			
I feel guilty because I am infected with HIV	2.11(1.23)	0.60								
People’s attitudes about HIV/AIDs makes me feel very bad.	2.23(1.25)	0.78								
I feel I am not as good as others because I’m infected with HIV.	2.01(1.23)	0.73								
Overall			28.44(7.68)	0.80(95% CI; 0.77-0.83)	0.92(95% CI; 0.87-0.95)	0.368**	0.328**	0.966	0.044	0.955

Pearson product-moment correlation coefficient; **p<0.001; # correlation between HIV stigma and PHQ-9; \neq correlation between HIV stigma and GAD-7

^aPossible score for each item 1-4; higher scores reflect a higher level of perceived HIV-related stigma

^bPossible score 3-12 on each sub-scale; higher scores reflect a higher level of perceived HIV-related stigma. ^{SD} Standard deviation. CFI = Comparative Fit Index. RMSEA = Root Mean Square Error of Approximation and TLI=Tucker Lewis Index. Cronbach α - Cronbach alpha

Table 3: Univariate linear Regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

Independent variables	N	Dependent variables									
		Personalised Stigma		Disclosure concerns		Public attitudes		Negative self-image		Overall HIV Stigma Score	
		B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value
Sociodemographic characteristics											
Age	450	-0.01 (-0.03, 0.02)	0.595	0.01 (-0.02, 0.02)	0.999	0.01 (-0.02, 0.04)	0.399	-0.01(-0.03, 0.03)	0.880	0.01 (-0.07, 0.08)	0.910
Gender	450										
Male		Ref		Ref		Ref		Ref		Ref	
Female		0.52(-0.06, 1.10)	0.080*	0.29 (-0.25, 0.83)		1.07 (0.35, 1.79)	0.003**	0.40 (-0.29, 1.08)	0.255	2.27 (0.54, 4.01)	0.010**
Marital Status	450										
Married		Ref		Ref		Ref		Ref		Ref	
Separated/Divorced/Widowed		0.54(0.03, 1.04)	0.038**	0.67(0.20, 1.14)	0.005**	0.25(-0.38, 0.87)	0.442	0.73(0.14, 1.32)	0.016**	2.18(0.67, 3.69)	0.005**
Single/never married		0.61(-0.14, 1.37)	0.111*	0.17 (-0.52, 0.87)	0.626	-0.43(-1.37, -0.51)	0.369	0.40 (-0.49, 1.28)	0.378	0.75(-1.50, 3.01)	0.512
Education Level	450										
Tertiary		Ref		Ref		Ref		Ref		Ref	
Secondary		-0.12(-1.36, 1.12)	0.847	0.08 (-1.06, 1.21)	0.896	0.68(-0.84, 2.21)	0.380	-0.03 (-1.46, 1.40)	0.967	0.61(-3.05, 4.26)	0.745
Primary		-0.31(-1.43, 0.81)	0.582	0.48 (-0.55, 1.51)	0.360	1.32(-0.06, 2.70)	0.061*	0.72 (-0.57, 2.01)	0.273	2.20(-1.10, 5.51)	0.191*
None		0.15(-1.01, 1.32)	0.794	1.23 (0.16, 2.30)	0.024**	1.80(0.36, 3.23)	0.014**	1.63 (0.29, 2.97)	0.018**	4.81(1.38, 8.25)	0.006**
Employment Status	450										
Formally Employed		Ref		Ref		Ref		Ref		Ref	
Self-employed		0.67(-0.16, 1.50)	0.112*	0.27 (-0.50, 1.05)	0.490	0.46(-0.57, 1.49)	0.385	0.73*(-0.24, 1.70)	0.141*	2.13(-0.36, 4.62)	0.094*
Other		-0.67(-2.33, 0.99)	0.429	-0.02 (-1.57, 1.53)	0.983	-1.14(-3.20, 0.93)	0.279	-0.35 (-2.29, 1.60)	0.726	-2.17(-7.15, 2.81)	0.392
Unemployed		0.51(-0.25, 1.26)	0.187*	0.33 (-0.37, 1.03)	0.360	0.18(-0.76, 1.11)	0.710	1.03 (0.15, 1.91)	0.022**	2.04(-0.22, 4.30)	0.077*
Currently living with	450										
Immediate family		Ref		Ref		Ref		Ref		Ref	
Relative/friend		0.86(-0.75, 2.47)	0.294	0.02(-1.47, 1.52)	0.975	0.18(-1.82, 2.18)	0.862	-0.45(-2.34, 1.45)	0.644	0.62(-4.23, 5.46)	0.802
Alone		0.01(-0.65, 0.66)	0.995	-0.25(-0.87, 0.36)	0.414	-0.06(-0.88, 0.76)	0.887	-0.07(-0.84, 0.70)	0.860	-0.38(-2.36, 1.60)	0.706
Asset index score ^a – mean (SD)	450	-0.12(-0.29-0.05)	0.171*	-0.13(-0.29-0.03)	0.109*	-0.11(-0.33-0.10)	0.310	-0.12 (-0.32-0.08)	0.244*	-0.48(-1.00-0.04)	0.068*
Clinical characteristics											
BMI – kg/m ² , mean (SD), OM = 4		0.004(-0.04, 0.05)	0.855	-0.03(-0.07, 0.02)	0.244	0.03(-0.03, 0.09)	0.309	-0.03(-0.18, 0.12)	0.708	-0.03(-0.18, 0.12)	0.708
Viral Load OM = 145	305										
≤ 1000 copies/ml		Ref		Ref		Ref		Ref		Ref	
> 1000 copies/ml		0.58(-0.28, 1.44)	0.183*	0.10(-0.70, 0.90)		0.07(-1.00, 1.14)	0.894	1.05 (0.08, 2.02)	0.033**	1.81(-0.79, 4.40)	0.172*

Months since HIV diagnosis	450	0.00(-0.00, 0.01)	0.346	-0.01 (-0.01, -0.00)	0.001**	-0.00(-0.01,0.00)	0.630	-0.01 (-0.01,0.00)	0.057*	-0.01(0.03,0.00)	0.091*
Months since cART initiation OM = 4	446	0.00(-0.00,0.01)	0.497	-0.01 (-0.01, -0.00)	0.001***	-0.00(-0.01,0.00)	0.202*	-0.01 (-0.01, -0.00)	0.031**	-0.02(-0.03, -0.00)	0.031**
Treatment characteristics											
HIV status disclosure	450										
Yes		Ref		Ref		Ref		Ref		Ref	
No		0.23(-0.77,1.23)	0.651	1.86 (0.94,2.77)	0.000***	0.67(-0.57,1.91)	0.287	0.72(-0.45,1.89)	0.228	3.47(0.49,6.46)	0.022**
Any current opportunistic infections	450										
No		Ref		Ref		Ref		Ref		Ref	
Yes		0.65(0.04,1.26)	0.037**	0.09(-0.48,0.65)	0.786	0.12(-0.64,0.88)	0.759	0.87 (0.16,1.59)	0.017**	1.72(-0.11,3.55)	0.065*
CMD comorbidity OM = 48	402										
Absence		Ref		Ref		Ref		Ref		Ref	
Presence		2.71(1.58, 3.84)	0.000***	0.18 (-0.91, 1.28)	0.741	1.09(-0.38, 2.55)	0.144*	3.07 (1.76, 4.39)	0.000***	7.06(3.71,10.41)	0.000***

Notes: Overall stigma scale represents the sum of all twelve items from the four subscales; A negative stigma score indicates less stigma. *CMD* – symptoms of depression and anxiety, *BMI* body mass index, *WHO* World Health Organisation, *Ref*- Reference category, *OM* observation with missing value, cART combination antiretroviral therapy, *a* score range = 0 to 7, *b* score range = 12 to 48. * p < 0.25; ** p < 0.05; *** p < 0.001

Table 4: Multivariate linear Regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

Independent variables	Dependent variables									
	Personalised stigma (n=402)		Disclosure concerns (n=450)		Public attitudes (n=450)		Negative self-image (n=402)		Overall HIV Stigma Score (n=402)	
	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value	B (95% CI)	p-value
Sociodemographic characteristics										
Gender										
Male	Ref				Ref				Ref	
Female	0.75(0.17, 1.34)	0.012**			1.07(0.35,1.79)	0.003**			2.00(0.21,3.80)	0.029**
Education Level										
Tertiary			Ref				Ref		Ref	
Secondary			-0.04(-1.14,1.07)	0.950			-0.05(-1.44,1.33)	0.939	-0.34(-3.83,3.16)	0.850
Primary			0.48(-0.52,1.48)	0.346			0.51(-0.73,1.74)	0.423	1.37(-1.75,4.50)	0.388
None			1.24(0.20,2.28)	0.019**			1.33(0.04, 2.62)	0.044**	3.32(-0.01,6.65)	0.051
Clinical characteristics										
Months since HIV diagnosis			-0.01(-0.01, -0.00)	0.007**						
Treatment characteristics										
HIV status disclosure										
Yes			Ref						Ref	
No			1.79(0.88,2.70)	0.000***					4.24(1.27,7.20)	0.005**
CMD comorbidity										
Absence	Ref						Ref		Ref	
Presence	2.67(1.55, 3.79)	0.000***					3.04(1.74, 4.34)	0.000***	6.67(3.40,9.94)	0.000***
Variance explained by the model Pseudo R-squared	6.76%		8.66%		1.89%		7.71%		10.17%	

Notes: Overall stigma scale represents the sum of all twelve items from the four sub-scales. CMD – symptoms of depression and anxiety, 95% CI - 95% confidence interval, Ref-reference category **p<0.05, ***p<0.001

Table 5: Multi-Group Confirmatory Factor Analysis for age and gender sub-groups

Invariance Steps	Gender	RMSEA	TLI	CFI	ΔCFI	Age	RMSEA	TLI	CFI	ΔCFI
Configural Invariance	Female	0.051	0.934	0.950		Older adults	0.040	0.960	0.970	
	Male	0.051	0.934	0.950		Young Adults	0.040	0.960	0.970	
Metric Invariance	Female	0.052	0.932	0.943	0.007	Older adults	0.042	0.957	0.964	0.006
	Male	0.052	0.932	0.943	0.007	Young Adults	0.042	0.957	0.964	0.006
Scalar Invariance	Female	0.050	0.936	0.943	0.000	Older adults	0.041	0.959	0.963	0.001
	Male	0.050	0.936	0.943	0.000	Young Adults	0.041	0.959	0.963	0.001
Strict Invariance	Female	0.048	0.941	0.942	0.001	Older adults	0.041	0.959	0.960	0.003
	Male	0.048	0.941	0.942	0.001	Young Adults	0.041	0.959	0.960	0.003

Notes: Criteria for an acceptable fit were a root mean square error of approximation (RMSEA) of < 0.06, and a comparative fit index (CFI), and a Tucker-Lewis index (TLI) of ≥0.90. Configural invariance - no constraints; Full metric invariance - with all factor loadings constrained equal. Scalar invariance - with all intercepts constrained equal; Strict invariance – with all factor loadings and intercepts fixed; Measurement invariance is assumed when ΔCFI is ≤0.01

Figure Legends

Supplementary Figure 1: Confirmatory factor analysis of the short version of the HIV Stigma Scale. Results show correlations between subscales (circles) and maximum likelihood estimates for the relation between subscales and items (rectangles). Sample (n = 435). Maximum likelihood estimates are standardised

Figure 1: Study recruitment flow chart





Figure 1: Study recruitment flow chart



Supplementary Figure 1: Confirmatory factor analysis of the short version of the HIV Stigma Scale. Results show correlations between subscales (circles) and maximum likelihood estimates for the relation between subscales and items (rectangles). Sample (n = 435). Maximum likelihood estimates are standardised

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6&8
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, describe analytical methods taking account of sampling strategy	8-9
		(e) Describe any sensitivity analyses	N/A
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	29
		(b) Give reasons for non-participation at each stage - see details in figure 1	29
		(c) Consider use of a flow diagram	29
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	23
Outcome data	15*	Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	25-27
		(b) Report category boundaries when continuous variables were categorized - see details in Table 1	23
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.